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 ABSTRACT 
γ-Secretase is a multi-subunit protease complex, composed of presenilin (PS1 or PS2), 
Nicastrin, Pen-2 and Aph-1, which generates the Alzheimer disease (AD) related 30-43 
amino acid long amyloid β-peptide (Aβ). The complex is also crucial for important cell 
signaling, such as the Notch receptor pathway. More than 200 different Familial AD 
(FAD) causing mutations have been identified. They are all restricted to either PS1, PS2 
or the amyloid β-precursor protein (APP), from which Aβ is generated, therefore proving 
how central γ-secretase mediated Aβ production is in AD pathogenesis. A common 
feature of FAD mutants is an increased Aβ42/Aβ40 ratio production. This results in a 
more amyloidogenic Aβ product and accelerated oligomerization and plaque formation.  
A number of γ-secretase inhibitors have been in clinical trials but so far there have 
been no major progress, due to mechanism-based side effects that is probably caused by 
impaired Notch signaling. It is therefore very important to develop novel therapeutic 
strategies targeting Aβ production without interfering with other crucial γ-secretase 
signaling pathwats. The aim of my thesis was to i) get a better understanding of the 
molecular basis behind the heterogeneous activity of γ-secretase resulting in different Aβ 
peptides, ii) to identify novel ways to target γ-secretase mediated Aβ production in a 
Notch sparing manner, iii) to explore the impact of a novel class of drugs called γ-
secretase modulators (GSMs) on different γ-secretase processes.  
In Paper I, we specifically investigated whether the membrane integration and/or 
the active site of PS would be affected by different PS1 FAD mutations, which cause an 
increased Aβ42/Aβ40 production ratio. We found that while some FAD mutations located 
in hydrophobic domains around the catalytic site (TMD6, H7 and TMD7) changed the 
membrane integration of PS1, all FAD mutations studied affected the structure of the 
catalytic site of γ-secretase. In Paper II the large hydrophilic loop of PS1 was examined. 
Interestingly, by using a deletion mutant strategy, we found that, similar to many FAD 
mutants, Aβ38, Aβ39 and Aβ40 were dramatically decreased in the absence of the loop, 
while Aβ42 was affected to a lesser extent, resulting in a net increase in the Aβ42/Aβ40 
ratio. Importantly, neither AICD nor NICD formation was impaired, suggesting that the 
integrity of the loop region is important for proper γ-site cleavage but not for the overall 
cleavage activity at the ε- site. To further study the mechanism of γ-secretase processing, 
we reported in Paper III the first study describing single residues in a γ-secretase 
component besides presenilin, such as Nicastrin, that affects the processing of γ-secretase 
substrates differently. In the final study, Paper IV, we studied the pharmacology of 
different GSMs and found that it is possible to generate in vivo potent second-generation 
γ-secretase-targeting modulatory compounds that are pre-selective for Aβ over Nβ 
production without affecting NICD formation. These findings may have major 
implications for the development of GSMs for AD and will be further discussed in the 
thesis.  
 
SAMMANFATTNING PÅ SVENSKA 
Alzheimers sjukdom är den vanligaste demenssjukdomen i dagens samhälle och 
representerar mer än 70% av alla demensfall. Sjukdomen drabbar främst äldre människor 
och beror på att nervceller i hjärnan dör allteftersom sjukdomen fortgår. Sjukdomen är 
uppkallad efter Alois Alzheimer som i början på 1900-talet var den första att beskriva de 
klassiska histologiska kännetecknen i hjärnan som förknippas med sjukdomen, så kallade 
plack och neurofibrillära nystan. De typiska förändringar som kan observeras beror 
främst på ansamling av två olika proteiner, Amyloid-beta (Aβ) och Tau. Det finns många 
former av Aβ, den vanligaste är Aβ40. En betydligt ovanligare variant är Aβ42 som är två 
aminosyror längre och som därför lättare klumpar ihop sig och bildar olika former av 
aggregat som är giftiga för nervceller. Aβ42-aggregaten är ett mellanstadium innan de 
slutligen skapar placken. Kvoten Aβ42/Aβ40 har visats vara förhöjd hos vissa 
Alzheimerpatienter och är en viktig markör för sjukdomsutvecklingen. Till skillnad från 
placken som skapas omkring nervcellerna så bildar Tau de aggregaten inne i cellerna som 
kallas för neurofibrillära nystan. Både Aβs och Taus aggregationsförlopp stör cellens 
funktioner.  
Från genetiska studier på patienter med ärftlig Alzheimer har man hittat 
förändringar i tre gener som kan kopplas till uppkomsten av plack. En av dessa gener 
bildar proteinet APP (amyloid precursor protein) som är grunden för Aβ-formerna. De 
andra två generna ger upphov till komponenter i γ-sekretaskomplexet, det enzym som 
klyver APP i cellens membran för att bilda Aβ. Ett sätt att hindra plackbildning, t.ex. med 
läkemedel, är att blockera γ-sekretaskomplexets aktivitet och på så vis förhindra 
klyvningen av APP. Tyvärr klyver γ-sekretaskomplexet även andra viktiga proteiner så 
bieffekterna från ett sådant läkemedel skulle kunna bli enorma. Många bieffekter beror på 
störningar i klyvningen av Notch, som är en betydelsefull molekyl under hela livet. I 
dagsläget finns det ingen effektiv behandling av Alzheimers sjukdom, eftersom 
nuvarande medicinering inte påverkar sjukdomsförloppet utan endast dämpar symptomen 
under en tid utan att stoppa nervcellsdöden. Behovet av att utveckla läkemedel som 
verkligen påverkar sjukdomsförloppet är därför enormt. En prioriterad sjukdomsstrategi 
är att minska bildandet av Aβ genom läkemedel. Som ovan nämnts är detta dock förenat 
med komplikationer och vi behöver hitta nya sätt att angripa γ-sekretaskomplexet på. För 
detta krävs ytterligare förståelse av biologin bakom komplexet. 
 I den här avhandlingen har jag i fyra studier undersökt skillnader och likheter i hur 
γ-sekretaskomplexet klyver APP och Notch. Detta för att bättre förstå de mekanismer och 
faktorer som påverkar valet av vilket protein som ska klyvas och hur APP kan klyvas på 
ett annat för att på så sätt minska bildandet av Aβ42.  
I studie I har ärftliga mutationer i presenilin, en av komponenterna i γ-
sekretaskomplexet, använts för att kunna förstå anledningen till den förhöjda Aβ42/Aβ40 
kvoten. Vissa mutationer som är belägna i närheten av enzymets aktiva del, gav upphov 
till förändringar av presenilin-proteinets integrering i cellens membran. Dessutom 
påverkade alla mutationer som undersöktes även strukturen av enzymets aktiva del, något 
som kan inverka på dess klyvning av APP och därmed leda till en ändrad Aβ42/Aβ40 
kvot.  
 
Strukturen av enzymets aktiva del var intressant nog även påverkad när ett annat 
viktigt område i presenilin studerades i studie II. När en specifik del i presenilin togs bort 
ledde detta till en dramatisk minskning av Aβ40, däremot minskade inte Aβ42 i lika stor 
utsträckning. Detta har visat sig vara betydelsefullt, eftersom en annan forskargrupp har 
påvisat samma resultat för möss med denna genförändring och dessa möss hade extremt 
höga nivåer av plack i hjärnan jämfört med vanliga möss. Vi har identifierat de 
aminosyror i presenilin som ger upphov till dessa förändringar men som inte påverkar 
klyvningen av Notch, vilket antyder att denna region kan vara en målregion för nya unika 
läkemedelsstrategier.  
I studie III fortsatte vi att undersöka orsakerna bakom skillnader i enzymets 
aktivitet och kunde som första forskargrupp rapportera att utöver presenilin kan 
mutationer i en annan komponent av enzymet (Nicastrin), leda till skillnader i klyvningen 
mellan APP och Notch. Vissa mutationer i Nicastrinmolekylen ledde till en sämre APP-
klyvning medan Notch påverkades mindre.  
Läkemedel som inte blockerar utan förändrar γ-sekretaskomplexets aktivitet är en 
mycket lovande behandling av Alzheimers sjukdom. Dock råder fortfarande osäkerhet 
kring hur ett förändrat enzym påverkar klyvningen av Notch. I studie IV studerade vi i 
detalj hur Notch påverkades av dessa läkemedel. Vi fann att det är möjligt att utveckla 
läkemedel som är mer selektiva mot att förändra APP-klyvningen än att påverka Notch.  
Sammanfattningsvis bidrar de identifierade mekanismerna och kunskaperna från 
studierna i denna avhandling med ytterligare viktig grundläggande förståelse om γ-
sekretaskomplexet och dess klyvningsaktivitet under normala betingelser och i sjukdom. 
Mer kunskap om γ-sekretaskomplexet och framförallt om hur olika typer av läkemedel 
påverkar enzymet och dess viktiga processer, såsom klyvningen av Notch, är oerhört 
viktig för fortsatt utveckling av effektiva och säkra läkemedel för långtidsbehandling av 
Alzheimers sjukdom. 
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1 INTRODUCTION 
 
1.1 ALZHEIMER DISEASE 
Alzheimer disease (AD), recognized as the most common form of dementia among the 
elderly population, is a progressive neurodegenerative disorder characterized by 
memory loss and cognitive impairment. In April 2012, WHO estimated that around 35 
million people worldwide have dementia and the numbers are expected to increase to 
106 million in 2050 (WorldHealthOrganization, 2012). AD represents 50-70% of all 
dementia cases and the prevalence increases exponentially with age; 1% of individuals 
between 60-65 years of age are affected and at the age of 85, up to 24-33% (Ziegler-
Graham et al., 2008). Due to the increasing life expectancy, the costs of the disease are 
growing enormously every year. According to a recent report, the estimated worldwide 
cost was $422 billion in 2009, an increase with 34% from 2005 (Wimo et al., 2010). 
Thus, besides tragically affecting the lives of AD patients and their close relatives by 
taking away their memory, awereness and language, AD is both a major public health 
problem and an economical concern. Therefore, efficient pharmacological treatment is 
an urgent matter.  
 The clinical features of AD initially start with a subtle progressive impairment of 
the episodic memory and orientation, which later develop to affect attention and 
executive functions, leading to impairments in decision-making and processing of 
information. As the cognitive dysfunctions continue, personality and behavioural 
alterations occur, such as paranoia, delusions, apathy and declined language function. 
Inevitably, these symptoms affect the cognitive and functional status further. After 
diagnosis, the patient usually lives 5-15 years and the cause of death is typically due to 
secondary illnesses such as pneumonia, other infections or malnutrition.  
 
1.1.1 Neuropathology 
The brains of AD patients are characterized by a decreased volume due to cortical 
atrophy along with enlargement of sulci and ventricles. The temporal and parietal lobes 
along with areas of the frontal cortex and the cingulate gyrus are particularly 
vulnerable. However, the sensory and motor regions as well as the occipital lobe are 
mainly unaffected. The atrophy, first observed in the hippocampus and entorhinal 
cortex, is due to; synaptic loss, degenerating neurites and a decreased number of 
neurons (Terry et al., 1991). A striking feature is the specific susceptibility of the 
cholinergic neurons, which provide the major cholinergic input to neocortex and 
cerebral cortex (Davies and Maloney, 1976; Whitehouse et al., 1981).  
 The major neuropathological hallmarks of AD were described in 1906 by Dr. 
Alois Alzheimer. He examined a post-mortem brain from the first documented case of 
AD, a 51-year-old patient named Auguste D (Alzheimer, 1907). Under the microscope, 
he observed intracellular neurofibrillary tangles (NFTs) composed of the 
hyperphosphorylated tau protein, and extracellular senile plaques mainly consisting of 
the aggregated amyloid-β peptide (Aβ), as shown in Figure 1 (Glenner and Wong, 
1984; Masters et al., 1985; Nukina and Ihara, 1986). Another hallmark of AD is 
increased inflammation, evidenced by increased presence of activated microglia and 
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astrocytes and abnormal levels of pro-
inflammatory cytokines. Tau is a microtuble-
associated protein mostly localized in the axons of 
neurons. When tau is hyperphosphorylated, it 
dissociates from the microtubules, causing 
impaired axonal transport that finally leads to 
retrograde degeneration and synapse loss (Iqbal 
and Grundke-Iqbal, 2005). There are more than 
30 phosphorylation sites in tau and in AD tau 
becomes abnormally hyperphosphorylated 
probably due to an imbalance between kinase and 
phosphatase activities (Pei et al., 2008). Once 
hyperphosphorylated, tau starts to self-assemble 
into paired filaments that in turn aggregate into 
the NFTs. There are two major forms of amyloid 
pathology in the AD brain; neuritic and diffuse plaques that are divided based on their 
morphology. The neuritic plaques have a fibrillar, compact core mainly composed of 
Aβ42, a 42 amino acid long Aβ specie, which plays a pivotal role in early plaque 
formation (Iwatsubo et al., 1994). These plaques stain positive for Congo red, a β-sheet 
specific dye for amyloid fibrils, in contrast to the amorphous diffuse plaques (Gowing 
et al., 1994). However, eventhough the diffuse plaques still contain aggregated Aβ42, 
they lack the dystrophic neurites, activated microglia and reactive astrocytes typically 
associated with the neuritic plaques. It has been suggested that the diffuse plaques 
represent an immature precursor state of the neuritic plaques, since they have been 
found in healthy, aged individuals with normal cognitive function. In addition, studies 
with transgenic mice have shown that diffuse aggregates form prior to the development 
of neuritic plaques (Urbanc et al., 1999). This hypothesis is further supported by studies 
on patients with Down's syndrome. These individuals typically develop AD early in life 
due to an extra chromosome 21, where the amyloid precursor protein gene (APP) is 
located (Olson and Shaw, 1969). Theses individuals show diffuse deposits already in 
their teenage years, whereas the neuritic plaques are developed later (Giaccone et al., 
1989; Rumble et al., 1989). There is also a rare third form of plaques named “cotton 
woll plaques” that is predominantly associated with some specific forms of familial AD 
(FAD) (Shepherd et al., 2009). Cotton wool pathology is also primary composed of 
Aβ42 but is extensively larger than both diffuse and neuritic plaques. Apart from 
plaques and tangles, the development of cerebral amyloid angiopathy (CAA) is a 
frequent pathological observation in AD (Hart et al., 1988). Here, Aβ is deposited into 
the walls of blood vessels and while Aβ42 is the predominate specie in pathology of the 
parenchyma; Aβ40 deposition is more common in the vessels (Miller et al., 1993; 
Suzuki et al., 1994).  
 The pathogenesis of AD is very complex and so called Braak-staging is a 
commonly used method to define and evaluate the different stages of the disease. 
Braak-staging takes both NFT and plaque pathology into account, which differs in 
regard to the regional distribution. NFT pathology is first observed in the enthorinal 
cortex, followed by spreading to the limbic structures such as hippocampus and 
Figure 1. The main hallmarks in AD. 
Extracellular senile plaques (black 
arrow) and intracellular neurofibrillary 
tangles (white arrow). Picture courtesy 
of Dr. Nenad Bogdanovic. 
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amygdala and finally occurring in neocortex (Braak and Braak, 1991). The plaque 
formation starts in the orbitofrontal and temporal cortices before spreading to the 
parietal cortex and neocortex. The spreading pattern of the pathology can be revealed in 
the symptoms; the earliest signs are short term memory problems, reflecting the initial 
damage to the hippocampus area. Later, when executive functions such as planning and 
initiation of actions are disturbed, the pathology can be observed in the prefrontal 
cortex and subcortical brain structures that controls these functions. However, the 
degree of cognitive decline does not correlate well with numbers of plaques, but rather 
with the extent of Tau pathology or levels of soluble Aβ (Arriagada et al., 1992; 
Naslund et al., 2000). Importantly, another neuropathological hallmark, which 
correlates well with disease severity is synapse loss (Terry, 2000; Terry et al., 1991). 
This is in accordance with that the severity of MRI brain atrophy measurments is well 
correlated with the conversion of mild cognitive impairment to AD (Jack et al., 2005; 
Risacher et al., 2009).  
 
1.1.2 Genetics and risk factors of AD 
Alzheimer disease is a multi-factorial disease, influenced by both environmental and 
genetic components. In general, there is no obvious pattern of genetic inheritance, 
thereby classifying most cases as sporadic AD. In a few percent of all AD patients, an 
autosomal dominant inheritance of mutations with almost complete penetration can 
be determined, so called familial AD (FAD). In most FAD cases the age of onset 
occurs before 65 years of age (early onset), while sporadic AD patients typically 
present the first symptoms after the age of 65 (late onset).  
 Genetic studies have revealed mutations in three different genes that cause the 
familial variant of the disorder. All three proteins encoded by these genes are 
involved in the generation of Aβ and several mutations in each gene have been 
identified. To date, 33 mutations in the APP gene on chromosome 21, 185 mutations 
in the presenilin 1 (PSEN1) gene on chromosome 14 and 13 mutations in the 
presenilin 2 (PSEN2) gene on chromosome 1 have been reported 
(http://www.molgen.ua.ac.be/ADMutations, (Goate et al., 1991; Levy-Lahad et al., 
1995; Sherrington et al., 1995)). APP is the precursor protein of Aβ, and Presenilin 1 
and 2 (PS1, PS2) are members of the γ-secretase complex, which catalyzes 
intramembrane proteolysis of the APP transmembrane domain (APP TMD) resulting 
in Aβ production. Identification and characterization of these genes have increased 
the understanding of the cause of the disease. For instance, many FAD mutations in 
PS1 and PS2 cause an increase in Aβ42/Aβ40 ratio either by decreasing the 
production of Aβ40 or by elevating Aβ42 generation (Yu et al., 2000). These 
observations strongly suggest that the Aβ42/Aβ40 ratio is of high relevance for the 
molecular pathogenesis of the disease. Regarding APP mutations, most increase the 
Aβ42/Aβ40 ratio, but some also enhance total Aβ levels. For example, duplication of 
the APP gene is linked to early onset AD with severe CAA (Cabrejo et al., 2006) and 
patients with Down's syndrome, having a third copy of APP, often develop AD 
starting as early as the age of 35 (Olson and Shaw, 1969; Tyrrell et al., 2001). Thus, 
besides changes in the Aβ42/Aβ40 ratio, increased levels of Aβ seems to be able to 
cause the the disease.  
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 Beyond the genes involved in FAD, several susceptibility genes have been 
suggested to contribute to the risk of developing AD. However, these genes have 
small effects and therefore larger sample sizes and genome-wide association studies 
(GWAS) are needed to gain enough power to detect them. Some possible 
susceptibility genes are; SORL1 (encoding for sortilin-related receptor), PICALM1 
(phosphatidylinositol-binding clathrin assembly protein), CR1 (the receptor for the 
complement C3b protein) and CLU (the clustrin gene) (Harold et al., 2009; Lambert 
et al., 2009). However, the most important and most replicated genetic risk factor for 
AD is the presence of one or two of the apolipoprotein E (ApoE) ε4 alleles. The 
APOE gene exists in three allelic variants, ε2, ε3 and ε4, encoding the corresponding 
isoforms of the protein. The only difference between the isoforms is the substitution 
of Cys to Arg at position 112 and 158. Nevertheless, these small differences can be 
crucial. The ε4 allele is associated with a dose-related increased risk for AD as well 
as an earlier onset of the disease (Corder et al., 1993; Saunders et al., 1993; 
Strittmatter et al., 1993), while the least common allele ε2 has been proposed to be 
protective (Corder et al., 1994). ApoE is a glycoprotein, whose function is to maintain 
the lipid and cholesterol homeostasis by transporting lipids and cholesterol (Martins 
et al., 2009). How the ε4 allele elevates the risk of developing AD is not known, but 
studies have shown higher Aβ burden in brains from AD patients carrying the allele. 
The isoforms of ApoE are also believed to differentially affect both the aggregation 
and clearance of Aβ (Kim et al., 2009), thereby influencing the risk of developing AD 
in an alternative way.  
 Besides the most important risk factors for AD, such as age and genetic factors, 
epidemiological studies have pointed out cerebral infarct and stroke, traumatic brain 
injury, hypertension and high cholesterol levels at midlife, cardiovascular disease, 
depression, diabetes mellitus, female gender, low physical and social activity as other 
influencing factors of AD (Qiu et al., 2009). Fortunately, some positive factors such 
as; education, physical activity, moderate alcohol consumption, challenging 
occupation, intake of fish, fruit and vegetables (i.e. omega-3 and anti-oxidants) have 
also been reported (Eskelinen et al., 2011; Hooshmand et al., 2012; Scarmeas et al., 
2009). The impact of some of these factors needs to be further evaluated, but it is very 
encouraging that there are ways on an individual level to reduce the risk to develop 
AD. Importantly, very recently it was also found that a mutation in APP, located 
close to the Aβ encoding sequence is protective against AD as well as cognitive 
decline in non-demented eldery. The mutation reduces β-secretase activity, which 
results in less Aβ production, providing further evidence for the pivotal role of Aβ in 
AD pathogenesis (Jonsson et al., 2012). 
 
1.2 THE AMYLOID PRECURSOR PROTEIN  
The Aβ peptide is derived from the amyloid precursor protein (APP) in a physiological 
normal pathway (Haass et al., 1993). APP is a type I transmembrane protein consisting 
of a single transmembrane domain, a large extracellular domain and a short 
cytoplasmic C-terminal region (Kang et al., 1987). It is a member of a conserved gene 
family including two homologues, APP like proteins 1 and 2 (APLP1 and 2). APP exits 
as three isoforms, which are 695, 751 and 770 amino acids in length and all variants 
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contain the Aβ domain. There is a ubiquitous expression of APP throughout the body 
but in neurons, APP695 is the predominant variant (Weidemann et al., 1989). The 
physiological function of APP is currently not fully elucidated, since two things 
complicate the analysis of the in vivo function of APP; i) a complex processing of APP 
generates several products that all are likely to perform specific functions and ii) the 
APP family share partially overlapping functions. During the processing of APP, the 
soluble N-terminal ectodomain (sAPP) is released by ectodomain shedding before the 
remaining membrane bound peptide is cleaved by γ-secretase, generating the Aβ 
peptide and the APP intracellular domain (AICD). Thus, besides full length APP there 
are three APP-derived metabolites that could be involved in different aspects of cell 
signaling.  
 The APP family shares conserved regions within the ectodomain and the ICD. 
However, the extracellular juxtamembrane domain within the Aβ region is very 
divergent and unique for APP. Although APLP1 and 2 lack the Aβ region, they are 
processed in a similar manner as APP. They undergo ectodomain shedding that releases 
soluble APLPs (Slunt et al., 1994), before being further processed in a γ-secretase 
dependent manner, generating Aβ-like fragments and intracellular domains (Eggert et 
al., 2004; Scheinfeld et al., 2002). In mice, while single knock-outs of the APP, ALPL1 
or 2 genes are viable, APP/APLP2 and APLP1/2 double knock-outs as well as the triple 
APP/APLP1/APLP2 knock-out result in prenatal lethality (Heber et al., 2000; Herms et 
al., 2004). Surprisingly, the APP/APLP1 double knock-out turned out to be viable and 
fertile (Heber et al., 2000). Together these data indicate an important role of the APP 
family in development and a redundancy between APLP2 and the other family 
members. In agreement with these data, APP and APLP2 are highly expressed in 
neurons during development and in adult tissues, while APLP1 is primarily found in 
the nervous system (Lorent et al., 1995). A study using RNA interference has 
demonstrated a critical role for APP in neuronal migration during development 
(Young-Pearse et al., 2007). In addition, APP has been implicated to stimulate neuronal 
outgrowth and to be neuroprotective (Kogel et al., 2005; Milward et al., 1992). 
However, several other functions have been proposed such as regulating stem cells 
(Kwak et al., 2006) and also having a role in axonal transport (Kamal et al., 2001). APP 
has also been reported to serve as a cell adhesion molecule and in trans-cellular 
interactions (Beher et al., 1996; Breen et al., 1991). This is supported by the 
observation that extracellular binding of heparin induces APP/APP dimerization (Gralle 
et al., 2006), mainly via the E1 domain and a GxxGD domain in the transmembrane 
region (Kaden et al., 2008) and that trans-dimerization of APP family members can 
promote cell-cell adhesion (Soba et al., 2005). 
 APP may also function as a cell surface-receptor (Kang et al., 1987), although the 
ligand has not been found. This is supported by the finding that AICD form a 
transcriptionally active complex with the adaptor protein Fe65 and the cromatin-
remodeling factor Tip60 (Cao and Sudhof, 2001; Cao and Sudhof, 2004). Some 
downstream target genes of AICD have been suggested, including; neprilysin, p53, 
APP itself and GSK-3β (Muller et al., 2008). However, there are also data suggesting 
that the γ-secretase dependent AICD production is not required for the proposed APP 
signaling, based on the findings that APP signaling could proceed normally in cells 
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Figure 2. Schematic illustration of APP processing in the non-amyloidogenic and amyloidogenic 
pathways. APP is cleaved by α-secretase in the non-amyloidogenic pathway, generating C83. C83 is 
further processed by γ-secretase that results in the release of the p3 peptide and AICD. In the 
amyloidogenic pathway, APP is processed by β-secretase followed by γ-secretase and Aβ and AICD is 
formed. 
deficient of γ-secretase or in γ-secretase inhibitor-treated cells (Hass and Yankner, 
2005). In addition to this controversy, it has even been proposed that Fe65 signaling 
could be executed independently of APP (Giliberto et al., 2008). Taken together, the 
role of AICD as a transcription regulator remains controversial.  
 It has been proposed that the ectodomain of APP is responsible for the majority 
of the functions of APP, since one protelytic fragment called sAPPα rescues the 
phenotypes observed in APP deficient mice (Ring et al., 2007). The mice have reduced 
body and brain weight, consistent with a role of APP for neuritic outgrowth, as well as 
impairments in learning and spatial memory that are associated with a decrease in long-
term potentiation (LTP) (Muller et al., 1994). Moreover, sAPPα has a potent role in 
neuroprotection as well as in growth promotion and neurotrophic activities. It is 
thought to promote proliferation of neuronal stem cells in the subventricular zone by 
acting as a cofactor for epidermal growth factor, EGF (Caille et al., 2004). On the other 
hand, another proteolytic fragment, sAPPβ has been associated with suppressed 
neuronal activity and for triggering neuronal death (Furukawa et al., 1996; Nikolaev et 
al., 2009). 
 
1.2.1 APP processing 
APP is transported through the secretory pathway to the plasma membrane. During the 
transportation, APP is post-translationally modified by N- and O-glycosylations, 
tyrosin-sulphations and phosphorylations (Weidemann et al., 1989). At the 
plasmamembrane, if not ectodomain shedded, APP is rapidly internalized due to the 
presence of the YENPTY internalization motif in the cytosolic domain (Lai et al., 
1995). Once endocytosed, APP is trafficked through the endocytotic and recycling 
pathways back to the cell surface, subjected to proteolytic events or degraded in the 
lysosomes. The mature protein is subjected to different proteolytic cascades, denoted 
the amyloidogenic and the nonamyloidogenic pathways, respectively, schematically 
shown in Figure 2. In the non-amyloidogenic pathway, APP is first cleaved within the 
Non-amyloidogenic pathway Amyloidogenic pathway 
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Aβ region by α-secretase, resulting in the soluble APPα fragment, sAPPα, (Esch et al., 
1990; Sisodia et al., 1990) and the membrane anchored C-terminal fragment of 83 
amino acid residues called C83. The latter fragment is subsequently cleaved by γ-
secretase generating non-toxic p3 peptides of different lengths and the APP 
intracellular domain, AICD (Gu et al., 2001; Haass et al., 1993; Sastre et al., 2001). The 
amyloidogenic pathway is initiated through the cleavage of APP at the N-termini of Aβ 
by β-secretase, which generates the secreted extracellular domain denoted sAPPβ, and 
the 99 amino acid long membrane integral C-terminal fragment, C99. Similar to C83, 
C99 is then processed by γ-secretase at multiple sites, which results in Aβ peptides of 
different lengths (γ-cleavage) and the AICD, which is released into the cytosol (Gu et 
al., 2001; Haass et al., 1993; Sastre et al., 2001). Interestingly, many APP FAD 
mutations are located in clusters close to the β- and γ-secretase cleavage sites, exerting 
their pathogenic effect by influencing the activity of these enzymes. For example, the 
APPswe mutation located just prior to the N-teminus of Aβ (K670N/M671L) (Mullan 
et al., 1992) increases total Aβ production by providing a better substrate for β-
secretase (Cai et al., 1993; Citron et al., 1992). In contrast, the mutations in the C-
terminal part of Aβ, such as the London, French, German, Florida and Austrian 
mutations modulate the γ-secretase complex to produce longer Aβ peptides, resuling in 
an increased Aβ42/Aβ40 ratio (Ancolio et al., 1999; Campion et al., 1999; De Jonghe et 
al., 2001; Eckman et al., 1997; Goate et al., 1991; Kumar-Singh et al., 2000). 
Moreover, mutations within the Aβ domain also affect the primary sequence and 
structure of Aβ, thereby leading to enhanced aggregation. The Artic mutation (E693G) 
enhances protofibril formation and has been shown to cause plaque pathology that does 
not stain Congo red-positive in post-mortem brains, while the Osaka mutation (∆E693) 
increases oligomerization without fibrilization (Basun et al., 2008; Nilsberth et al., 
2001; Philipson et al., 2012; Tomiyama et al., 2008).  
The enzymatic mechanism of γ-secretase has been subjected to intense 
investigations. There is now compelling evidence for a sequential processing model of 
APP, and likely other substrates, by γ-secretase (Kakuda et al., 2006; Qi-Takahara et 
al., 2005; Sato et al., 2003). Based on the identification of particular tri- and tetra 
peptides generated from C99, a model where APP is sequentially processed along two 
production lines; Aβ49>Aβ46>Aβ43>Aβ40 or Aβ48>Aβ45>Aβ42>Aβ38 has been 
proposed, see Figure 3 (Takami et 
al., 2009). Thus, the 
endoproteolytic cleavage starts at 
the ε-site, which results in the 
generation of AICD while Aβ49 or 
Aβ48 are further processed to 
shorter Aβ fragments in a precursor 
product manner. As the consecutive 
cleavage progresses, less 
hydrophobic Aβ fragments are 
formed and increase the probability 
of their release into the extracellular 
space or the cytosol. In addition, in 
Figure 3. Aβ product lines. APP is suggested to be 
sequentially processed along two production lines. The 
product line preference of γ-secretase is determined by 
the initial position of the ε-cleavage site and releases 
AICD. Aβ49 or Aβ48 are then further processed to 
shorter fragments. 
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vivo experiments have shown that the product line preference of γ-secretase is 
determined by the initial position of the ε-site (Funamoto et al., 2004), i.e. whether γ-
secretase cleaves at position 48-49 or 49-50 in the C99 sequence. This is also supported 
by a recent study, which reports that FAD mutations in either APP or PS impair the 
initial cleavage at the ε-site of the predominate Aβ49>>Aβ40 product line and/or 
impair the fourth cleavage, resulting in decreased Aβ40/Aβ43 and Aβ38/Aβ42 ratios 
(Chavez-Gutierrez et al., 2012; Golde et al., 2012).  
 
1.2.1.1 α-Secretase 
In 1990, it was described that APP was cleaved within the Aβ sequence, thus 
precluding Aβ formation (Esch et al., 1990), by a protease that was named α-secretase. 
α-Secretase was identified as a metalloprotease and several candidates for the 
proteolytic activity exist, all being members of the ADAM family (a disintegrin and 
metalloprotease), including ADAM9, ADAM10 and ADAM17 (also known as TNFα) 
(Koike et al., 1999; Lammich et al., 1999; Slack et al., 2001). Proteases of the ADAM 
family are type I transmembrane proteins that require the addition of a zinc ion in order 
to be proteolyticly active (Edwards et al., 2008). It was for a long time unclear which 
candidate protease was responsible for ectodomain shedding of APP, since knock-out 
and knock-down studies of ADAM9, 10 or 17 gave unclear results. For example; the 
APP ectodomain shedding was mainly unaltered in cells derived from mice deficient of 
either ADAM9, 10 or 17 and knock-down studies of the same proteins by RNA 
interference reduced the shedding process by 20-60% (se review (Lichtenthaler et al., 
2011)). Therefore, it was suggested that all three proteases share the α-secretase activity 
and that proteolytic activity can be rescued by the others proteases if one is absent. In 
contrast, other substrates to the ADAM family are mainly cleaved by a specific ADAM 
protease. Recently however, it was shown that ADAM10 is responsible for the α-
secretase activity in primary neurons (Jorissen et al., 2010; Kuhn et al., 2010). By using 
systematic knock-down of ADAM9, 10 and 17 by RNA interference, or cells prepared 
from conditional ADAM10 knock-out mice, both groups observed an almost complete 
reduction of sAPPα in the absence of ADAM10. This is in line with a report that 
ADAM10 and APP show coordinated expression in the human brain (Marcinkiewicz 
and Seidah, 2000). The proteolytic activity of α-secretase occurs mainly at the plasma 
membrane (Sisodia, 1992), and apart from APP, ADAM10 sheds more than 30 other 
membrane bound proteins, including Notch . Notch is an important signaling molecule 
in cell differentiation during development as well as in adulthood and is cleaved by γ-
secretase in a similar manner as APP. In agreement, ADAM10 knock-out mice that die 
at embryonic day E9.5 display a phenotype reminiscent of mice carrying a loss-of-
function of the Notch-allele (Hartmann et al., 2002). Interestingly, ADAM10 itself is a 
substrate for γ-secretase activity, after being ectodomain shedded by ADAM9 
(Tousseyn et al., 2009).  
 
1.2.1.2 β-Secretase 
The Aβ initiating and rate limiting enzyme of the amyloidogenic pathway (Vassar, 
2004), β-secretase, was cloned and identified by five groups (Hussain et al., 1999; Lin 
et al., 2000; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999). β-Secretase or β-
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site APP cleaving enzyme-1 (BACE1) is a membrane bound aspartic protease with its 
active site in the lumen/ extracellular space (Hong et al., 2000). There are two isoforms 
of BACE (Vassar, 2004), but the BACE2 protease is not involved in the amyloidogenic 
pathway, since mice deficient in BACE1 do not produce Aβ (Cai et al., 2001; Roberds 
et al., 2001). Moreover, when these mice were crossed with APPswe transgenic mice, 
they gave rise to rescued memory deficits (Ohno et al., 2004). BACE1 is ubiquitously 
expressed in high levels in the brain, and especially in the neurons, while BACE2 
expression is mainly occurring in non-neural cells. APP is highly expressed in the brain 
as well and these high dual expression levels make the brain the primary tissue for Aβ 
generation. This is one explanation to why AD is a disease affecting the brain even 
though APP is expressed throughout the whole body. The function of BACE1 remains 
unclear, but it has been shown to regulate voltage dependent sodium channels (Kim et 
al., 2007) and many other substrates such as the neuregulin-1, platelet selectin 
glycoprotein ligand-1, Type I α-2,6-sialyltransferase, interleukin-like receptor II, 
APLP1 and 2 and Aβ itself (Dislich and Lichtenthaler, 2012). Very recently, by using a 
novel method for quantification and identification of secretome proteins, 34 substrates 
of BACE1 were reported. Importantly, some of these proteins were validated in vivo 
using BACE1 kock-out mice or mice treated with BACE1 inhibitors (Kuhn et al., 
2012). Previously, only a few BACE substrates have been validated and associated 
with a clear biological function. It is of importance to validate BACE1 candidate 
substrates, since many substrates were identified using over-expression systems that 
may lead to artificial substrate/protease interactions. The initial reports of the BACE1 
knock-out mice showed that they were viable, fertile and had no major behavioral or 
developmental deficits (Cai et al., 2001; Roberds et al., 2001). However, in more recent 
studies these mice were shown to display hypomyelination in the peripheral nervous 
system accompanied by an accumulation of uncleaved neuregulin-1, as well as 
displayed impaired axonal guidance of olfactory sensory neurons (Rajapaksha et al., 
2011; Willem et al., 2006). Thus, some of the physiological functions of BACE1 
concerns myelination and in addition, dys-regulation of neuregulin-1, which have also 
been implicated with schizophrenia (Stefansson et al., 2002; Williams et al., 2003). 
Interestingly, in accordance with that BACE1 is required for proper axon guidance 
(Rajapaksha et al., 2011), some of the newly identified BACE1 substrates are 
associated with synapse formation and neurite outgrowth, indicating a function of 
BACE1 in the development of the brain (Kuhn et al., 2012).  
 
1.2.2 Aβ 
Aβ peptides of various lengths, 30-43 amino acids, are generated by the sequential 
cleavage of APP by β- and γ-secretase. Aβ is mainly produced in neurons during 
normal metabolism and is present in the cerebrospinal fluid (CSF) and brain of healthy 
people during the course of their life (Haass et al., 1992; Seubert et al., 1992; Vigo-
Pelfrey et al., 1993). Therefore, the presence of Aβ does not lead to neuronal injury, but 
the neurodegeneration leading to dementia is instead a cause of the pathological 
aggregation of Aβ. However, the physiological function of Aβ is not known. Under 
normal conditions, there is a balance between production and degradation of Aβ since it 
is rapidly cleared from the brain by different enzymes. Neprilysin and insulin degrading 
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enzyme are the major Aβ degrading enzymes in vivo (Farris et al., 2003; Iwata et al., 
2000). In addition, Aβ can also be endocytosed at the synapse, phagocytosed by 
microglia and astrocytes. Alternative, Aβ can be transported out from the brain, 
mediated by the low-density lipoprotein receptor related protein (LRP)-1 (Shibata et al., 
2000). In the other direction, Aβ can pass the blod-brain-barrier from the systemic 
circulation by binding to the receptor for advanced glycation end-products (RAGE) 
(Deane et al., 2003). Interestingly, in AD patients and animal AD-models the LRP1 
expression is reduced (Shibata et al., 2000), while RAGE has been reported to be 
upregulated (Deane et al., 2003; Lue et al., 2001). This suggested a role of these 
mechanisms in sporadic AD 
 Aβ40 is the major Aβ specie produced, and is also predominant in human CSF 
and plasma. Apart from Aβ40, less abundant and shorter Aβ species including Aβ37, 
Aβ38 and Aβ39 have been found in cell medium by several groups (Qi-Takahara et al., 
2005) (Beher et al., 2002; Wang et al., 1996). The longer Aβ42 peptide is very 
fibrillogenic and prone to aggregate since it is more hydrophobic and is also the form 
that is particularly important for early plaque formation (Iwatsubo et al., 1994). The 
length of the C-terminal part of Aβ strongly affects the rate of polymerization, for 
example Aβ42 forms fibrils very rapidly at lower concentration than Aβ40 (Jarrett et 
al., 1993). In addition, trace amounts of Aβ42 and Aβ43, the latter recently found in 
amyloid deposits of human AD brains (Welander et al., 2009), have a seeding effect of 
other soluble Aβ peptides for the formation of amyloid plaques in vivo (Jarrett et al., 
1993). Even longer peptides such as Aβ45, Aβ46, Aβ48 and Aβ49 have been identified 
in both brain homogenates from APP-transgenic mice and cell lysates by combining 
immunoprecipitation and SDS/urea gel techniques (Qi-Takahara et al., 2005; Yagishita 
et al., 2006; Zhao et al., 2005). All different peptides are generated by the stepwise 
cleavage by γ-secretase along the two product lines, as described earlier in section 1.2.1 
APP processing. The longer Aβ peptides are however believed to stay in the membrane 
due to their hydrophobic properties.  
 The polymerization process of monomeric Aβ into fibrils and sequentially 
amyloid plaques is a complex multi-step procedure involving different oligomeric 
intermediates. The process is not fully understood, partly due to that there is no 
common experimental description of the different identified Aβ oligomeric species 
reported. Thus there are difficulties in comparing data and results between different 
research groups (Benilova et al., 2012). Therefore, it is likely that some of the identified 
species have similar or overlapping properties. It is also important to note that several 
of the oligomers have only been found in vitro, and consequently, their in vivo 
relevance and properties are uncertain. The in vitro oligomeric assemblies of Aβ 
described in the literature include; dimers and trimers (Podlisny et al., 1995; Shankar et 
al., 2008; Walsh et al., 2000), a 56-kD Aβ assembly called Aβ*56 (Lesne et al., 2006), 
Aβ-derived diffusible ligands (ADDLs) (Gong et al., 2003; Lambert et al., 1998), 
globulomers (Barghorn et al., 2005; Gellermann et al., 2008) and protofibrils (Harper et 
al., 1997; Walsh et al., 1997). These soluble oligomeric forms are all candidates to be 
the most toxic pathogens in AD, as described in the next section 1.2.3 The Amyloid 
cascade hypothesis.  
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1.2.3 The Amyloid cascade hypothesis 
Alzheimer disease is a complex multi-factorial disease and since a definitive disease 
mechanism is still not found, many different hypotheses explaining the pathogenesis, 
resulting in the neurodegeneration, has been proposed. One of the predominant and 
most supported hypothesis regarding the cause of AD is the amyloid cascade 
hypothesis. The hypothesis, initially formulated two decades ago, postulates that the 
major causing event in AD is the pathological production and accumulation of Aβ in 
the brain, due to abnormalities in amyloid precursor protein (APP) metabolism (Hardy 
and Higgins, 1992). This drives the AD pathogenesis by initiating cascades of events 
such as; hyperphosphorylation of tau and formation of NFTs, activation of microglia 
and astrocytes resulting in oxidative stress, synaptic spine loss and dystrophic neurites 
culminating in progressive neuronal loss and synaptic dysfunction, leading to dementia, 
summarized in Figure 4. Two key observations resulted in the initial formulation of the 
hypothesis. First, Aβ was identified as the main component of neuritic plaques 
(Glenner and Wong, 1984; Masters et al., 1985) and secondly, mutations in the APP 
and PSEN genes were found in families with early onset AD (Goate et al., 1991; Levy-
Lahad et al., 1995; Sherrington et al., 1995). Since FAD has a similar phenotype as 
sporadic AD, except an earlier age of onset, it was believed that the amyloid deposition 
could explain the pathogenesis of all types of AD. Initially, the main focus was on the 
insoluble Aβ fibrils in plaques as key 
mediators of the disease process. 
However, the focus has shifted and 
now the soluble Aβ oligomers are 
considered as the most toxic species 
(Haass and Selkoe, 2007; Hardy, 
2006). In accordance, an update of the 
amyloid cascade hypothesis was made 
in 2002 (Hardy and Selkoe, 2002). In 
agreement, studies have shown that 
the soluble oligomers are better 
correlated to the degree of cognitive 
decline and synaptic loss than the 
plaques (DaRocha-Souto et al., 2011; 
McLean et al., 1999; Naslund et al., 
2000). Furthermore, rats exposed to 
Aβ oligomers produced by cultured 
cells showed inhibited hippocampal 
LTP, and most importantly, 
immunodepletion of Aβ in the cell 
medium prevented the observed effect 
(Walsh et al., 2002). LTP is a process 
that correlates learning and memory 
and it was reported that cell-derived 
oligomers could interfere with 
memory functions in rats (Cleary et Figure 4. The Amyloid cascade hypothesis. 
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al., 2005). Finally, studies have shown that dimers and trimers of Aβ secreted from 
cells or Aβ dimers isolated from AD patients can induce loss of spines and synapses in 
the hippocampus (Shankar et al., 2007; Shankar et al., 2008) and lead to reduced 
formation of LTP in hippocampal brain slices (Klyubin et al., 2008).  
 There is a strong biochemical and genetic support for the amyloid cascade 
hypothesis. Aβ oligomers have been shown to be toxic to neurons and synapses and are 
also found to be elevated in brains from individuals with AD (Selkoe, 2002). FAD 
mutations in the APP and PSEN genes give rise to either elevated total Aβ levels, an 
increase in the Aβ42/Aβ40 ratio or enhance the oligomerization of Aβ, leading to early 
onset AD (St George-Hyslop, 2000). In addition, patients with Down's syndrome 
typically develop AD-like dementia and pathology, as described in sections 1.1.1 
Neuropathology and 1.1.2 Genetics and risk factors of AD. Furthermore, genes 
identified in the late onset form of the disease also provide support for the hypothesis. 
Patients carrying the APOE ε4 allele, which is the major genetic risk factor, have higher 
Aβ burden in their brains (Schmechel et al., 1993) and many GWAS have identified 
genetic variations, which also associate with Aβ related mechanisms (Reitz, 2012). The 
use of biomarkers in AD has been widely increased during the last decade. Biomarkers 
include imaging, such as MRI measuring brain atrophy, FDG-PET determining glucose 
metabolism and PET amyloid imaging as well as CSF analysis of Aβ42, total tau and 
phosphorylated tau. In 2010, Jack et al. proposed a model that relates AD biomarkers 
to clinical symptom severity (Jack et al., 2010). This model and many other studies 
have indicated that Aβ accumulation begins decades before the first cognitive signs 
occur. This was recently confirmed in a longitudinal study using FAD patients. They 
reported that levels of Aβ42 in CSF declined 25 years before expected symptom onset 
and that Aβ deposition began 15 years before the first cognitive symptoms were 
manifested (Bateman et al., 2012) 
 However, it remains unclear how Aβ induces the formation of NFTs. APP-
transgenic mice with reduced levels of endogenous tau could improve Aβ-mediated 
behavioral deficits (Roberson et al., 2011; Roberson et al., 2007). In addition, tau 
mutations that cause frontotemperal lobe dementia show tau pathology similar to AD 
without the appearance of Aβ depositions (Hutton et al., 1998). Nevertheless, patients 
with Down’s syndrome have Aβ plaques before the occurrence of tangles (Lemere et 
al., 1996). There are concerns regarding the inconclusive outcomes, such as cognitive 
improvement, from clinical trials with compounds or antibodies targeting Aβ or 
components in the amyloid cascade hypothesis (Reitz, 2012). However, these studies 
are mainly conducted in patients with mild to moderate AD and the disease is very 
likely to be too advanced in order to observe a disease-modifying effect. Importantly, 
most studies have not included CSF biomarkers in the trial designs, making it difficult 
to know whether the substances have hit the proposed target.  
 
1.3 THE γ-SECRETASE COMPLEX 
The proteolytic activity of γ-secretase is a key step in the pathogenesis of AD, since it 
generates the Aβ peptide and a detailed knowledge about this complex will help to 
understand at least a part of the complex mechanisms of the disease. 
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Figure 5. The components of the γ-secretase complex. Stars indicate the catalytic active Asp257 
and Asp385 residues. 
 The γ-secretase complex is a promiscuous aspartyl protease, responsible for the 
final intramembrane cleavage of various type I transmembrane proteins, such as APP. 
It only cleaves the substrate after ectodomain shedding (Struhl and Adachi, 2000). The 
γ-secretase is a multi-protein complex composed of at least four members; presenilin 
(PS), Nicastrin, anterior pharynx defective-1 (Aph-1) and presenilin enhancer-2 (Pen-
2), as shown in Figure 5 (Edbauer et al., 2003; Kimberly et al., 2003). All components 
are initially co-localized in the ER, however the assembly of the complex is tightly 
regulated to ensure cell and tissue specific levels of active γ-secretase complexes. The 
PS molecules undergo endoproteolysis upon assembly of all members in ER/early 
Golgi compartment, generating the active N-terminal and C-terminal fragment (NTF 
and CTF) (Thinakaran et al., 1996). First, Nicastrin and Aph-1 form a sub-complex to 
bind and stabilize the PS holoprotein, and then Pen-2 initialize the γ-secretase activity 
by facilitating the endoproteolysis of PS (reviewed in (Dries and Yu, 2008)). During 
the transport of the complex through the secretory pathway, the maturation of Nicastrin 
occurs in the Golgi compartment by complex glycosylation. After further post-
translational modifications of Aph-1 and Nicastrin by palmiotylation (Cheng et al., 
2008), the mature and active complex reaches its functional sites, on the plasma 
membrane and in the endosomes/lysosomes. The nature of the active γ-secretase was 
for a long time a debate. However, multiple lines of evidence strongly suggest that PS, 
Nicastrin, Aph-1 and Pen-2 are sufficient for γ-secretase activity. For instance, co-
expression of these components in Saccaromyces cerevisiae, which lack endogenous γ-
secretase activity, results in γ-secretase activity (Edbauer et al., 2003). The same has 
been shown in Drosophila and mammalian cells (Hayashi et al., 2004; Kimberly et al., 
2003; Takasugi et al., 2003; Zhang et al., 2005a). Active γ-secretase complexes has also 
been succesfully isolated from post-mortem human brain (Farmery et al., 2003).  
 
1.3.1 γ-Secretase components 
The stoichiometry and size of γ-secretase is still under debate. The most accepted 
model is a 1:1:1:1 stoichiometry, which has got support from various biochemical 
approaches (Fraering et al., 2004; Sato et al., 2007). However, a dimerization of PS 
Pen-2 
Presenilin (PS) 
Nicastrin 
Aph-1 
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(Schroeter et al., 2003), thus giving a 2:2:2:2 relationship, has also been proposed. Both 
suggestions find support in the estimated native molecular weight of the complex, 
ranging from 250kDa to 2MDa, depending on which method has been used for analysis 
(Edbauer et al., 2002; Kimberly et al., 2003; Li et al., 2000a; Osenkowski et al., 2009). 
The difference in the molecular weight could be explained by additional interacting 
components. For example, a number of proteins have been found to putatively interact 
with γ-secretase and to affect the Aβ production. These proteins include the 
transmembrane glycoprotein CD147 and TMP21 a protein involved in protein transport 
and quality control in ER and Golgi. (Chen et al., 2006; Zhou et al., 2005). In addition, 
TMP21, the synaptic protein syntaxin 1, NADH dehydrogenase ubiquinone iron-sulfur 
protein 7 (NDUFS7), a tubulin polymerization promoting protein (TPPP), the 
contactin-associated protein 1, Erlin-2 and the voltage-dependent anion channel 1 
(VDAC1) as well as several other proteins have been associated with active γ-secretase 
in preparations from rat brain (Frykman et al., 2012; Hur et al., 2012; Teranishi et al., 
2012; Teranishi et al., 2010). Members of the tetra spanin web, involved in cell fusion, 
proliferation, adhesion and migration processes (Levy and Shoham, 2005), were also 
identified as γ-secretase associated proteins in PS deficient fibroblasts stably expressing 
epitope-tagged PS1 or PS2 (Wakabayashi et al., 2009). Combined, these findings 
suggest that γ-secretase activity could be extensively regulated by multiple signaling 
pathways and interacting proteins. 
 
1.3.1.1 Presenilin 
Two human presenilin homologues, PS1 and PS2, were identified in 1995 (Levy-Lahad 
et al., 1995), (Sherrington et al., 1995) and they are evolutionary conserved between 
species. PS has nine transmembrane domains (TMDs) (Henricson et al., 2005; Laudon 
et al., 2005; Oh and Turner, 2005; Spasic et al., 2006) and share an average protein 
homology of 63%, but up to 95% within the TMDs. The fact that many more 
pathogenic mutations are found in the PS1 gene than in the PS2 gene suggest a more 
critical role for PS1 in the onset of the disease. Furthermore, PS1 knock-out mice are 
embryonic lethal and have dramatically reduced γ-secretase activity, while PS2-/- mice 
are viable and have preserved γ-secretase activity (De Strooper et al., 1998; Herreman 
et al., 1999). In addition, PS1 and PS2 complexes show differences in activity and 
sensitivity to γ-secretase inhibitors (Borgegard et al., 2011; Lai et al., 2003; Zhao et al., 
2008). Thus, these proteins appear to possess overlapping but different functions.  
 After assembly of all γ-secretase components, PS undergoes endoproteolysis, an 
event that has been proposed to occur via autoproteolysis (Wolfe et al., 1999). Indeed, 
the domain that contains the PS cleavage site, encoded by exon 9, is hydrophobic and 
may integrate into the membrane. A major site after amino acid 298 and a minor 
between amino acid 292/293 were identified as the autoproteolytic cleavage site 
(Podlisny et al., 1997). In accordance, a recent report observed that endoproteolysis of 
PS generates tri-peptides (Fukumori et al., 2010), consistent with the stepwise 
endoproteolysis of APP (Takami et al., 2009). This is also in line with that some PS 
FAD mutations change the precision of the endoproteolyc site (Fukumori et al., 2010). 
The PS NTF and CTF constitute the active form of PS by forming a stable heterodimer. 
Each fragment harbours one of the two catalytic aspartate residues (Asp257 and 
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Asp385 in PS1) in TMD 6 and 7 (Steiner et al., 1999; Wolfe et al., 1999) that make up 
the catalytic site of γ-secretase. There are several pieces of evidence that the aspartates 
exert the catalytic function of the enzyme and thus identify the γ-secretase complex as 
an aspartyl protease; i) replacement of Asp257 or Asp385 with alanine prevents Aβ 
formation and abrogates endoproteolysis (Wolfe et al., 1999), ii) γ-secretase transition 
state inhibitors that bind to the active site of an aspartyl protease directly bind to both 
NTF and CTF (Berezovska et al., 2000; Esler et al., 2000; Li et al., 2000b; Seiffert et 
al., 2000) and iii) this binding is abolished by mutations of the aspartate residues 
(Wrigley et al., 2004). 
 Most FAD mutations are situated within or flanking the conserved hydrophobic 
TMDs and are, except for the Δexon9 mutation, missense mutations resulting in single 
amino acid change or deletion of two amino acid residues. In general, all FAD 
mutations in PS1 and 2 cause an increase in the Aβ42/Aβ40 ratio, either by decreasing 
the production of Aβ40 or by increasing the Aβ42 generation (Bentahir et al., 2006; 
Citron et al., 1997; Kretner et al., 2011; Kumar-Singh et al., 2006; Scheuner et al., 
1996). The presence of the mutations in TMDs, their scattered distribution and the 
overall finding that they change the complex’s cleavage preference, i.e. yielding an 
increase in the Aβ42/Aβ40 ratio, suggests that they may cause a conformational change 
of PS1. Especially since the topology of a membrane protein is largely dependent on 
the hydrophobicity of the TMDs (von Heijne, 2006). In addition, inherited mutations in 
a growing array of membrane proteins frequently lead to improper folding and 
trafficking (Nakamura and Lipton, 2009). A suggested conformational change of PS1 
in the complex could lead to subtle alterations in the presentation of the substrate to the 
catalytic site or the substrate binding properties, thereby causing the observed shift in 
the Aβ42/Aβ40 ratio. Nevertheless, how the mutations induce the conformational 
change of PS remains to be elucidated. Strikingly, there are almost no known mutations 
in the large cytoplasmic loop of the PS molecule and this domain differ extensively 
between PS1 and PS2 (Stromberg et al., 2005). The loop is 110 amino acids in length 
for PS1 and 84 amino acids in length for PS2 and shares only 16% homology when 
preforming protein blast alignment (www.blast.nvbi.nlm.nih.gov). β-Catenin has been 
reported to bind to the loop of PS1 but not PS2 (Saura et al., 2000; Yu et al., 1998) and 
apart from endoproteolysis the loop region is also cleaved by caspases (Kim et al., 
1997). Interestingly, some research groups have addressed the role of the large 
hydrophilic loop with somewhat contradicting results, leaving its function still unclear. 
The loop has been shown to be dispensable for γ-secretase activity since the lethal 
phenotype of PS1 deficient mice could be rescued by the introduction of a PS1 
molecule lacking the loop (Xia et al., 2002). This is consistent with a study reporting 
that the Aβ production was not altered by PS1 and 2 FAD mutations when the Aβ 
levels were measured in cells with mutated PS molecules with or without the loop 
(Saura et al., 2000). However, a protective role of the loop has been suggested, since 
knock-in mice with a PS1 molecule lacking most of the hydrophilic loop but with a 
retained endoproteolytic site, showed reduced Aβ40 generation along with exacerbated 
plaque pathology (Deng et al., 2006). 
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1.3.1.2 Nicastrin 
Five years after the discovery of PS, another member of the γ-secretase complex, 
Nicastrin, was identified by PS affinity purification (Yu et al., 2000). Nicastrin is a type 
I transmembrane protein with a short cytoplasmic tail and a large ectodomain 
containing multiple glycosylation sites. Nicastrin requires PS for its maturation into a 
glycosylated protein (Edbauer et al., 2002; Siman and Velji, 2003) but, in contrast, the 
glycosylation is not essential for γ-secretase activity or complex assembly (Herreman et 
al., 2003). However, Nicastrin is dependent on PS in order to alter the conformation of 
its ectodomain, which contains the DYGIS motif that is critical for γ-secretase activity 
(Shirotani et al., 2003). One part of the Nicastrin ectodomain shows similarity to 
aminopeptidases and the transferrin receptor superfamily (Fagan et al., 2001), 
suggesting that Nicastrin could act as a receptor and thus be involved in initial substrate 
recognition. It was reported that the glutamate residue Glu333 in the Nicastrin 
ectodomain physically interacted with the N-terminus of APP- and Notch derived γ-
secretase substrates (Shah et al., 2005) and mutations of this residue led to reduced APP 
processing compared to wild type Nicastrin (Dries et al., 2009). The substrate receptor-
like role for Nicastrin was later challenged, as both in vivo and in vitro studies found 
that the mutation of Glu333 (332 in mouse) was important for the maturation and 
assembly of the γ-secretase complex rather than the activity (Chavez-Gutierrez et al., 
2008). Moreover, another member of the GxGD-type aspartyl proteases, SPPL2b does 
not require additional co-factors in order to be proteolyticly active. It still displays 
similar substrate requirements as the γ-secretase, i.e. an ectodomain-shedded substrate 
(Martin et al., 2009), indicating that substrate selection may not depend on Nicastrin. 
Thus, it remains unclear whether Nicastrin is involved in substrate selectivity or has a 
more general role in the stabilization and maturation of the γ-secretase complex (Zhang 
et al., 2005b). 
 
1.3.1.3 Aph-1 and Pen-2 
By performing genetic screening in C. elegans, two additional co-factors beyond PS 
and Nicastrin were identified, Aph-1 and Pen-2 (Francis et al., 2002; Goutte et al., 
2002). Aph-1 deficent C. elegans lacks the anterior pharynx and therefore, the missing 
protein was named, anterior pharynx defective-1, Aph-1 (Goutte et al., 2002). There are 
two homologues of Aph-1 in humans; Aph-1a and b that share 56% of the amino acid 
sequence. Furthermore Aph-1a can be spliced into two isoforms, generating Aph-1aS 
(short) and Aph-1aL (long) and in addition there is a third isoform in mice, Aph-1c. 
Aph-1 is the most stable component of the complex and has a seven transmembrane 
topology, in which the N-terminus resides in the lumen and the C-terminal part faces 
the cytosol (Fortna et al., 2004). It has been suggested to function as a scaffold for the 
complex, thus being important for complex assembly as a conserved GxxxG motif in 
TMD4 is central for the binding of PS and Pen-2 (Niimura et al., 2005). In addition, 
two highly conserved histidine residues in TMD5 and TMD6 are important for 
interaction to the other γ-secretase components and for activity, since mutations in these 
residues lead to decreased Aβ formation (Pardossi-Piquard et al., 2009b). Pen-2 has a 
hairpin topology, containing two TMDs with the N- and C-terminus facing the lumen 
(Crystal et al., 2003). The C-terminus and TMD1 of Pen-2 is vital for endoproteolysis 
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of PS and thus for activation of the γ-secretase complex as well as stabilizing the 
generated PS fragments (Kim and Sisodia, 2005b; Prokop et al., 2005; Prokop et al., 
2004). In turn the N-terminus is important for the interactions with PS (Crystal et al., 
2003).  
 
1.3.2 The structure and active site of γ-secretase 
No detailed information about the structure of γ-secretase is available, since the 
complexity and the numerous TMDs of the γ-secretase complex have made structural 
analysis such as X-ray crystallography challenging. Nevertheless, recent data from 
negative stain- and cryo-electron microscopy suggest the formation of a transmembrane 
barrel-like structure with an aqueous catalytic cavity (Lazarov et al., 2006; Ogura et al., 
2006; Osenkowski et al., 2009; Renzi et al., 2011). However, with a low resolution of 
12-15Å it is not possible to get an understanding of the structure at a molecular level. 
More detailed information of the catalytic site has been provided by studies using 
substituted cysteine accessibility method (SCAM). These studies show that the catalytic 
pore is formed mainly by PS TMD6 and 7 that face each other (Sato et al., 2006; Tolia 
et al., 2006) and that both TMD1 and 9 contribute with residues that are water 
accessible (Sato et al., 2008; Takagi et al., 2010; Tolia et al., 2008). Importantly, both 
the GxGD motif in TMD7 and the conserved PAL motif between TMD8 and 9, were 
suggested to be part of the hydrophilic cavity as they were accessible to water (Sato et 
al., 2006; Sato et al., 2008; Tolia et al., 2006; Tolia et al., 2008). In addition, it was 
recently reported that the loop domain of Pen-2 was accessible to water from the 
luminal side, thus contributing to the active site (Bammens et al., 2011). The loop in 
Pen-2 was also cross-linked to PS1 CTF, suggesting that it is in close proximity to 
TMD9 that show a comparable accessibility pattern as the loop in Pen-2 (Bammens et 
al., 2011; Tolia et al., 2008). NMR analysis of the PS1-CTF has been performed 
suggesting that the TMD7 formed a half helix and the part with the GxGD region had a 
loose random coil conformation, whereas TMD8 was fully integrated as a helix and the 
TMD9 had a nicked helix (Sobhanifar et al., 2010). Finally, all these results are 
supported by previously performed general interaction studies of the subunits, using 
cross-linking and co-immunoprecipitation techniques. In these studies PS NTF and 
CTF were shown to interact, PS TMD4 interacted to the hydrophobic domain in Pen-2 
and the CTF with Aph-1, which also is in close contact with Nicastrin (Fraering et al., 
2004; Kim and Sisodia, 2005a; Steiner et al., 2008; Watanabe et al., 2005).  
In contrast to the active site, less information is available for the location of the 
initial docking site of the substrate. There is, however, compelling evidence for the 
existence of such site, to where the substrate initially binds before it is passed to the 
active site for proteolytic processing. For example, by immobilizing a transition-state 
(TS) analogue inhibitor on an affinity column, it was shown that C99 still can be co-
purified with the γ-secretase complex, thus binding a site different from the active site 
that was presumably interacting with the immobilized inhibitor (Esler et al., 2002). 
Further, helical peptides that mimic the transmembrane domain of C99 can inhibit γ-
secretase processing of APP (Das et al., 2003) by occupying another site different from 
the transition-state analogue inhibitor binding site (Kornilova et al., 2003). By using 
affinity labeling of helical peptides, the presenilin NTF-CTF interface has been 
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identified to contribute to the binding site (Kornilova et al., 2005). Moreover, later both 
fragments were individually shown to be the target of substrate mimicking peptides 
(Sato et al., 2008). It has also been implicated that the GxGD and PAL motifs, which 
are parts of rather flexible structures, are important for substrate interaction as these 
region are highly vulnerable to mutations when monitoring substrate processing (Perez-
Revuelta et al., 2010; Steiner et al., 2000; Wang et al., 2006a; Yamasaki et al., 2006). 
Interestingly, the exon 9 encoding hydrophobic domain that harbours the 
endoproteolytic site has been suggested to function as a plug in the catalytic pore. By 
using an exon 9 mimicking peptide it was demonstrated that the hydrophobic domain 
did not interact with the active site but rather the docking site, since there were no 
competition between the TS analogue inhibitor L-685,458 and the exon 9 peptide 
(Knappenberger et al., 2004). Thus, the intact loop may function as a gatekeeper, 
keeping PS in its inactive form as a holoprotein and preventing substrates to enter the 
active site (Fukumori et al., 2010; Knappenberger et al., 2004). This is consistent with 
a report, where the GlpG, a rhomboid protease in E.coli that contain a similar 
proteolytic chamber as γ-secretase (Wang et al., 2006b), was found to have a flexible 
loop that sealed the pore and following its removal induced substrate binding (Baker et 
al., 2007). Interestingly, the PS1 FAD mutation ∆exon 9 that is not endoproteolysed 
due to the lack of the endoproteolytic cleavage site, may be constantly active due to the 
removal of this regulatory mechanism. As described in section 1.3.1 γ-Secretase 
components, PS1 FAD mutations have been proposed to change the conformation of 
PS1 in the complex, leading to subtle alterations in the presentation of the substrate to 
the catalytic site or the substrate binding properties and thereby causing the observed 
shift in Aβ42/Aβ40 ratio. Indeed, induced conformational changes in the catalytic site 
of PS by certain PS FAD mutations have been reported. By using a FLIM assay, it was 
shown that PS1 FAD mutations increased the NTF and CTF proximity compared to 
wild type, thereby leading to a more closed conformation of the complex (Berezovska 
et al., 2005). A closed conformation of the complex was proposed to stabilize the active 
site of γ-secretase and C99 in a way that favoured the Aβ42 production. This is 
supported by observations using pharmacological treatments with substances that either 
increased or decreased the Aβ42/Aβ40 ratio also led to induction of a closed or open 
state, respectively (Lleo et al., 2004; Uemura et al., 2009). In addition, genetic 
manipulation of γ-secretase components gave the same results, thus suggesting that the 
conformation of the γ-secretase complex correlated with the Aβ42/Aβ40 ratio (Uemura 
et al., 2009). The finding that PS FAD mutations induce changes in the catalytic site of 
γ-secretase was further confirmed by another report, which showed that the PS1 FAD 
mutation L166P and to some extent G384A affected the pull down of active γ-secretase 
complexes when using a photolabeled transition state analogue inhibitor (Kornilova et 
al., 2005).  
 
1.3.3 The function of γ-secretase  
The γ-secretase is a promiscuous enzyme complex and the list of its substrates still 
continues to grow. To date, there are more than 90 known substrates for the γ-secretase 
complex (Lleo and Saura, 2011). There is no identified consensus binding motif in the 
substrates, but the substrates must have undergone ectodomain shedding, which leads 
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to a short ectodomain with less than 50 amino acids (Struhl and Adachi, 2000). 
However, not only ectodomain shedding is a prerequisite for γ-secretase activity. The 
juxtamembrane domain, the TMD as well as the cytoplasmic domain of the substrates, 
are important in order to be correctly processed by γ-secretase (Hemming et al., 2008; 
Ren et al., 2007; Zhang et al., 2002). The growing list of substrates and the poor 
sequence specificity of γ-secretase have led to the suggestion that the complex acts as a 
cleaning lady of the membrane, removing transmembrane domains when the full-length 
proteins have fulfilled their purpose (Kopan and Ilagan, 2004; Lichtenthaler et al., 
2011). Indeed, the feature of the γ-secretase complex, hydrolysis of a peptide bond 
within the transmembrane region, is a highly conserved process called regulated 
intramembrane proteolysis (RIP) (Brown et al., 2000). There are three classes of 
proteases that posses the ability to perform intramembranous cleavage; the GxGD-type 
aspartyl proteases, the S2P-metalloproteases, and the rhomboid serine proteases (Beel 
and Sanders, 2008). The GxGD-type aspartyl proteases consist of γ-secretase, the signal 
peptide peptidase (SPP), the SPP-like proteases (SPPL) and the type IV prepilin 
peptidases. Some intracellular domains (ICD) released by RIP are translocated to the 
nucleus and are involved in signal transduction, implying a role of initiating signaling 
for the γ-secretase complex. In fact, during the last decade RIP has emerged as a novel 
cell signaling mechanism that involves most type I and II transmembrane proteins 
through a sequential cleavage event. Fore the type I transmembrane proteins, the large 
soluble extracellular fragment of the substrate is first released by a cleavage in the 
ectodomain close to the membrane, resulting in a membrane bound CTF fragment. This 
is referred to as ectodomain shedding and is executed by members of the ADAM 
family, BACE1, BACE2 and matrix metalloproteases. The RIP process are mostly 
regulated at the level of shedding and this can either be a constitutive activity or 
regulated by different stimuli, including ligand binding and subcellular localization 
(Hayashida et al., 2010). Upon ectodomain shedding, the membrane-associated CTF is 
subsequently cleaved a second time within the membrane, releasing the ICD. Some 
substrates also release Aβ-like peptides, such as Notch, APP like protein (APLP) 1 and 
2, CD44 and interleukin-1 receptor II (Eggert et al., 2004; Kuhn et al., 2007; Lammich 
et al., 2002; Okochi et al., 2002; Yanagida et al., 2009).  
 A well established example of a pathway mediated by RIP is the Notch signaling 
pathway, schematically shown in Figure 6. The Notch receptors (Notch 1-4) were the 
next γ-secretase substrates to be discovered after APP (Schroeter et al., 1998). During 
trafficking through the secretory pathway, Notch is cleaved at the S1 site by furin-like 
convertase forming a heterodimer (Blaumueller et al., 1997; Logeat et al., 1998). At the 
plasma membrane, the heterodimer is activated by binding of its ligands Jagged or 
Delta that is presented by neighbouring cells (Nye and Kopan, 1995), inducing 
ectodomain shedding of Notch at the extracellular S2 site by ADAM10 (van Tetering et 
al., 2009) This results in a shorter membrane bound form, NotchΔE or NEXT, which is 
an immediate substrate for the γ-secretase (De Strooper et al., 1999; Schroeter et al., 
1998). γ-Secretase processes NotchΔE in at least two different positions, the S3 and the 
S4 site. The S3 cleavage is equivalent to the ε-cleavage in APP and generates the Notch 
intracellular domain (NICD) (Schroeter et al., 1998), while the S4 site corresponds to 
the γ-site in APP and releases Aβ-like peptides, called Nβ (Okochi et al., 2002). The 
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physiological function of Nβ is not known but NICD translocates to the nucleus, where 
it is involved in transactivation of HES (Hairy/Enhancer of split) genes. These genes 
are involved in non-neural cell fate decisions and are critical for the development of 
many tissues and organs (Jarriault et al., 1995). This vital signaling pathway is 
especially assigned the Notch1 receptor and consequently, Notch1 deficiency leads to 
an embryonic lethal phenotype associated with severe developmental deficits (Huppert 
et al., 2000; Swiatek et al., 1994). In adults, Notch1 is constitutively expressed, having 
important roles in various cells and tissues, such as hematopoiesis, the immune system, 
gastrointestinal tract, pancreas, myogenesis, and self-renewing organs (Groth and 
Fortini, 2012; Kopan et al., 1994; Pui et al., 1999; Radtke et al., 2004; van Es et al., 
2005). 
 Apart from APP and Notch, other γ-secretase substrates include; the APP 
homologues APLP1 and 2; the sorting receptors SorlA and sortilin (that are important 
for intracellular sorting and trafficking of cargo proteins); ligands such as, Jagged and 
Delta, (which are the Notch ligands); ligands for receptor tyrosine kinase Eph receptors, 
EphrinB, involved in neuritogenesis and angiogenesis; CD44, E-cadherin and N-
cadherin, which are cell adhesion molecules; various receptors including ErbB4, a 
receptor of growth factors; p75-neurotrophin receptor (p75-NTR) involved in axonal 
transport and neuronal survival and interleukin-1 receptors that are a part of the 
immune response (Eggert et al., 2004; Elzinga et al., 2009; Georgakopoulos et al., 
2006; Jung et al., 2003; Kanning et al., 2003; Kuhn et al., 2007; Lammich et al., 2002; 
Marambaud et al., 2002; Marambaud et al., 2003; Ni et al., 2001; Nyborg et al., 2006; 
Nye and Kopan, 1995; Scheinfeld et al., 2002). Most commonly, it is the ICD that acts 
as the signaling molecule, either by translocation into the nucleus and inducing the 
transcription of target genes or by acting as a cytosolic signaling molecule. The first is 
Figure 6. Schematic illustration of Notch processing. During trafficking through the secretory 
pathway, Notch is cleaved at the S1 site by furin-like convertase forming a heterodimer, which is 
further transported to the plasma membrane. After ligand binding the heterodimer is ectodomain 
shedded at the S2 site by ADAM10. Finally, γ-secretase processes NotchΔE at two different 
positions, the S3 and the S4 site generating NICD and Nβ.  
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in analogy to NICD and includes CD44-ICD that has been shown to increase the 
activation of the transcription co-activator CBP and the ICD of N-cadherin, which 
promotes degradation of the transcription factor CREB binding protein (Marambaud et 
al., 2003; Okamoto et al., 2001). Examples of non-nucleus targeted ICDs are; ephrinB-
ICD that leads to the activation of Src-family kinases and the p75-NTR-ICD, which is 
important for formation/disassembly of receptor complexes (Georgakopoulos et al., 
2006; Jung et al., 2003; Kanning et al., 2003). Importantly, most ICDs are rapidly 
degraded and may not have a signaling function. However, the extracellular fragment 
released by RIP can also mediate signaling functions, like when the ectodomain from 
growth factors start a signaling transduction by activating neighbouring cells. E.g. after 
the cleavage of cytokine tumour necrosis factor α (TNFα) both the ectodomain and the 
ICD act as signaling molecules, but targeting different cells (Black et al., 1997; Fluhrer 
et al., 2006).  
 
1.3.4 Regulation of γ-secretase activity 
Both PS and Aph-1 exist as homologues, yielding several distinct γ-secretase 
complexes with the possible combinations of PS and Aph-1 homologues. Due to the 
presence of PS1 and PS2 homologues and the three Aph-1 isoforms, at least six distinct 
complexes exist in humans that have different properties and functions (Hebert et al., 
2004; Saura et al., 1999; Serneels et al., 2005; Shirotani et al., 2004b). Indeed, both PS 
homologues co-immunoprecipitate independently with each of the Aph-1 variants 
(Hebert et al., 2004; Serneels et al., 2005; Shirotani et al., 2004b). Moreover, the 
multiple glycosylation forms of Nicastrin also contribute to the hypothesis that different 
γ-secretase complexes exist with distinct functions. So, although γ-secretase is a 
promiscuous enzyme cleaving many substrates, complexes containing different variants 
of subunits can have altered activity and substrate specificity. PS1 containing 
complexes catalyze the majority of the Aβ production (Borgegard et al., 2011; De 
Strooper et al., 1998) and PS1 and PS2 complexes show differences in activity and 
sensitivity to some γ-secretase inhibitors (Borgegard et al., 2011; Lai et al., 2003; Zhao 
et al., 2008). In addition, it has also been reported that cadherins are only processed by 
PS1 containing complexes, since the catenin-protein-p-120, which binds cadherins and 
recruits them to the γ-secretase complex for processing, only binds a sequence in PS1 
CTF that is not present in PS2 (Saura et al., 2000; Yu et al., 1998). Furthermore, PS1 
knock-out mice are embryonic lethal and have dramatically reduced γ-secretase 
activity, while PS2-/- are viable and have preserved γ-secretase activity (De Strooper et 
al., 1998; Herreman et al., 1999). Moreover, different cell types may use complexes 
containing different PS homologues, since it has been shown that there are mainly PS2 
containing complexes in microglia (Jayadev et al., 2010), while in fibroblasts only a 
minor pool of PS2 complexes exist (Franberg et al., 2011). Regarding the Aph-1 
isoforms, mice knocked-out of one of the three APH-1 genes, all display differences in 
phenotype and γ-secretase activity. In addition, complexes containing Aph-1a are 
crucial for γ-secretase mediated Notch signaling during development (Ma et al., 2005; 
Serneels et al., 2005). It has also been reported that Aph-1b/c complexes processes 
neuregulin as Aph-1b/c knock-out mice have accumulation of neuregulin CTF 
(Dejaegere et al., 2008) and a phenotype similar to mice deficient of neuregulin 
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(Stefansson et al., 2002). Furthermore, Aph-1b complexes produce more of the longer 
Aβ forms in proportion to the shorter forms and also induce a more closed 
conformation of PS1 (Serneels et al., 2009), similar to the effect of certain PS1 FAD 
mutations monitored by a FLIM assay (Berezovska et al., 2005). Finally, complexes 
containing Aph-1b are the major contributors of γ-secretase activity in human brain 
(Serneels et al., 2009). However, all complexes with combinations of human Aph-1 
isoforms together with FAD mutations in PS1 or PS2 can generate Aβ42 (Shirotani et 
al., 2007). Substrate processing is also controlled by the subcellular localization of the 
enzyme. For example, glycosylated Nicastrin may promote cell surface localization of 
γ-secretase (Yang et al., 2002) and thus increase the cleavage of substrates that are 
mainly expressed at the plasma membrane, such as Notch and cadherins. In contrast, 
factors that retain or localize γ-secretase to internal compartments, such as the 
endosomes, facilitate the Aβ production, as the amyloidogenic processing of APP 
mainly occur there due to high BACE1 activity (Haass et al., 1993; Koo and Squazzo, 
1994). Such abilities are for example assigned to i) the Calsenilin protein that inhibits 
the trafficking of the PS1 CTF fragment and Aph-1 to the cell surface (Jang et al., 
2011) ii) two members of the G-protein-coupled receptors, the β2-adrenergic and δ-
opioid receptors, which increase the endocytosis and trafficking of γ-secretase to the 
endosomes by interacting with PS (Ni et al., 2006; Teng et al., 2010). In addition, the ε-
cleavage of APP differs in the endosomes and at the plasma membrane (Fukumori et 
al., 2006), implying subcellular localization dependent properties of the γ-secretase 
complex that could be due to differences in lipid composition or pH. γ-Secretase 
interacting protein TMP21 also regulates γ-secretase by binding to PS in the 
intracellular compartments. In contrast to other factors that retain the complex at a 
subcellular localization, TMP21 decreases Aβ formation and interestingly not affects 
the ε-cleavage (Chen et al., 2006; Pardossi-Piquard et al., 2009a). Moreover, there is a 
growing list of γ-secretase interacting proteins that regulate Aβ generation, as described 
in section C.1 γ-Secretase components. Finally, it is an appealing strategy to 
pharmacologically regulate the γ-secretase complex with the aim to alter the 
metabolism of the Aβ42 peptide, which plays a central role in AD pathogenesis. 
Inhibition and modulation of the γ-secretase complex will be discussed in detail in 
section 1.4.2 Future treatment strategies. 
 
1.4 TREATMENT OF AD 
More than 100 years have passed since Dr. Alzheimer first described the 
neuropathological hallmarks of the disease that later got his name. Despite the 
tremendous research efforts during the last three decades, there is currently no 
treatment available to cure or to effectively stop the development of the disease. There 
are only two types of symptomatic drugs approved for treating AD, cholinesterase 
inhibitors and a N-methyl-D-aspartic acid (NMDA) - receptor antagonist, memantine. 
However, the knowledge of the neurobiology in AD has increased enormously these 
past decades and numerous attempts to therapeutically affect the progression of AD are 
currently under investigation.  
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1.4.1 Current treatment 
The strategy using cholinesterase inhibitors is based on the observation that the 
cholinergic system is specifically vulnerable and disrupted in AD (Wenk, 2003). The 
cholinergic system is important for higher cognitive functions in the brain such as 
memory and attention. Cholinergic neurons in the nucleus basalis of Meynert, which 
provide the major cholinergic input to cerebral cortex, have been shown to be 
selectively degenerated in AD (Davies and Maloney, 1976; Whitehouse et al., 1982). 
Cholinergic signaling between cells is mediated by the neurotransmitter acetylcholine 
and cholinesterase inhibitors block the degradation of the neurotransmitter. Increasing 
concentration of acetylcholine in the synaptic cleft prolongs the signaling and thus 
enhances the activity of the remaining cholinergic neurons. There are three different 
cholinesterase inhibitors on the market and they are used for treating patients with mild 
to moderate AD. NMDA receptors can be over-stimulated by glutamate, leading to 
hyper-excitatory signal transduction and dysfunction that in turn propagates neuronal 
death (Greenamyre and Young, 1989; Meldrum, 1990). Studies have associated 
abnormally high glutamate levels with AD (Greenamyre and Young, 1989; Penney et 
al., 1990). Memantine resets NMDA receptor activity by blocking the effects of excess 
glutamate, allowing normal physiological transmission to occur (Chohan and Iqbal, 
2006). 
 
1.4.2 Future treatment strategies 
Epidemiological studies have demonstrated that long-term treatment of various agents 
including non-steroidal anti-inflammatory drugs (NSAIDs) (aspirin, ibuprofen, 
naproxen etc), estrogen and cholesterol-lowering drugs reduces the risk of AD (Cote et 
al., 2012; Henderson, 2008; Li et al., 2010). Similar studies have also associated the 
intake of Mediterranean food, vitamin B, social and physical activity with decreased 
risk of developing the disease (Eskelinen et al., 2011; Hooshmand et al., 2012; 
Scarmeas et al., 2009). Other treatment strategies involve regenerative mechanisms that 
may increase neurogenesis, which can be induced by drugs, cell transplantation, 
mitochondrial targets, antioxidants and nerve growth factor (NGF) treatment 
(Ankarcrona et al., 2010; Eriksdotter-Jonhagen et al., 2012; Marutle et al., 2007; Olson 
et al., 1992; Pieper et al., 2010). NGF stimulates growth of cholinergic neurons and 
delivery of NGF through an implantate in the nucleus basalis of Meynert can improve 
cognition in mild AD patients (Eriksdotter-Jonhagen et al., 2012). However the 
therapeutic benefits and sometimes the safety of some of these approaches are in 
general low (Carlsson, 2008; Lukiw, 2012) or still remains to be shown. Beyond these 
approaches, the current main disease modifying strategies in AD involves; i) drugs 
targeting Tau, ii) elimination of the aggregation of Aβ and destabilizing Aβ oligomers, 
iii) improving the clearance of Aβ or iv) compounds that reduce or modulate the Aβ 
generation (Reitz, 2012). Regarding tau pathogenesis, the main approaches are 
inhibitors of tau-phosphorylating kinases or drugs that inhibit the aggregation or 
promote disassembly of aggregated Tau. However, since AD is increasingly considered 
as a multi-factorial and heterogeneous disease, the use of a drug-cocktail covering 
multiple targets may be a successful approach.  
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1.4.2.1 Targeting Aβ 
A major research focus of the therapeutic treatment is compounds targeting the Aβ 
pathway, aiming at reducing Aβ levels in the brain. One approach is the prevention of 
Aβ aggregation or neutralizing the toxicity of Aβ oligomers by destabilizing them. The 
concern with these types of compounds often involves difficulties in passing the blood-
brain-barrier (BBB) or safety issues. A few compounds have however entered phase II 
clinical trials. For example, PBT1 was shown to pass into the brain, although in small 
amounts, in both transgenic mice and human volunteers. In the brain, it binds to 
amyloid plaques and interferes with the binding of Aβ to copper and zinc and thus 
reducing Aβ aggregation (Opazo et al., 2006). Unfortunately, the trials were later 
stopped due to toxicity reasons (Adlard et al., 2008), but a second-generation cousin, 
PBT2, has better BBB permeability and shows some improvement in cognitive or 
executive function in animal experiments and mild AD patients (Adlard et al., 2008; 
Lannfelt et al., 2008). In addition, ELND-005 that modulates Aβ misfolding and 
aggregation by interacting with Aβ was also reported to have problems with toxicity 
(Reitz, 2012). Another way of suppressing Aβ aggregation is to enhance its clearance. 
This could either be accomplished with compounds that increase the activity of Aβ 
degrading enzymes such as insulin degrading enzyme and neprilysin or by using active 
or passive immunization.  
 Immunization as a therapy was developed after an observation that vaccination 
with Aβ42 in an AD transgenic mouse model prevented plaque formation (Schenk et 
al., 1999). Antibodies can trigger Aβ clearance in different ways; i) by inducing 
phagocytosis of Aβ by microglia that bind to Aβ and promote solubilization ii) by 
binding to peripheral Aβ in the blood and function as a peripheral sink and thus 
promoting the efflux of Aβ from the brain. Unfortunately, the first vaccination study in 
human was halted due to severe meningoencephalitis caused by T-cell response in 
some participants (Gilman et al., 2005). However, most patients developed Aβ-
antibody titres that lasted up to 4.6 years and had some cognitive improvement. In 
addition, post-mortem examinations revealed almost complete removal of the amyloid 
plaques in some subjects even though end-stage dementia symptoms still occurred at 
the time of death (Vellas et al., 2009). Lately, new vaccines that only target the B-cell 
epitope have been developed and recently results from the phase II trial with the CAD-
106 antigen was reported. No meningoencephalitis was observed, CAD-106 was well 
tolerated and an immune-response was found in around 70% of all mild-to-moderate 
AD patients (Winblad et al., 2012). An alternative approach is the use of passive 
immunization; here the patients are injected with antibodies against Aβ. Several 
antibodies including; bapineuzumab from Pfizer, Johnson & Johnson and Elan and 
solanezumab from Lilly, are now being tested and they are in general well tolerated and 
show some effect on Aβ clearance (Reitz, 2012). The outcome of clinical phase III 
trials with bapineuzumab and solanezumab are important steps forward in our efforts to 
address whether anti-Aβ treatment is an effective therapeutic approach in AD. 
Unfortunately, in August 2012 the trials using intravenous administration of 
bapineuzumab were discontinued, due to failure to show any impact on cognitive or 
functional performance in patients with mild to moderate Alzheimer disease. 
Bapineuzumab, is raised aginst the N-terminal domain of Aβ and targets the plaques. 
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The failure of this antibody may either high-light the problems of targeting Aβ at later 
stages of AD, or the antibody was not efficient enough in lowering Aβ. Future analysis 
of biomarker data from these trials will be very important in fully interpretating the 
obtained clinical data. Anyhow, solanezumab exhibits quite different properties 
compared to bapineuzemab and recognizes the mid-part of Aβ and does only bind 
various forms of soluble Aβ and not plaques. Thus, the solanezumab trials will more 
specifically address if oligomeric forms of Aβ indeed contributes to the toxicity in AD. 
Interestinlgy, recent press releases from Eli Lilly suggest that some positive signs from 
the solanezumab trials have been observed. 
  
1.4.2.1.1 Secretases as a therapeutic target of AD 
APP is processed by both α-, β- and γ-secretase and therefore, it is natural to consider 
all secretases as potential targets in the prevention of AD. In order to reduce Aβ 
generation, secretases can be targeted either by promoting α- secretase activity or by 
inhibiting β- and γ- secretase. There are a number of evidence that α- and β-secretase 
compete for cleavage of APP (Lichtenthaler, 2011), since over-expression of ADAM10 
leads to elevated sAPPα in parallel with decreased β-secretase cleavage and 
subsequently Aβ production (Postina et al., 2004). The same is also observed in 
experiments using pharmacological stimulation of α-secretase by muscarinic activation 
(Bandyopadhyay et al., 2007). Moreover, the genetic APPswe mutation results in 
increased BACE1 cleavage accompanied with reduced sAPPα levels. Thus, increasing 
α-secretase activity pharmacologically is a valid therapeutic strategy in AD 
(Fahrenholz, 2007). These approaches involve increased ADAM10 expression that is 
induced by retinoic acid, which is already used in clinic for psoriasis (Donmez et al., 
2010; Tippmann et al., 2009) or by enhancing its activity using M1 muscarinic agonists 
(Lichtenthaler, 2011). Other alternatives involve treatment with cholesterol-lowering-
drugs since these reduces the cholesterol content in certain areas and thus indirectly 
elevates α-secretase activity that take place outside the cholesterol rich domains (Kojro 
et al., 2010). Importantly, an increased long-term activation of ADAM10 needs to be 
thoroughly evaluated as ADAM10 cleaves more than 30 other substrates apart from 
APP. 
 β-Secretase initiates the amyloidgenic pathway, thus being an important drug 
target for Alzheimer disease. However, there have been some key challenges regarding 
compounds affecting BACE1. The catalytic site of BACE1 is unusually large (Turner 
et al., 2005), representing a major challenge of designing compounds that are able to 
block the active site and still effectively penetrate the BBB. Moreover, a growing list of 
β-secretase substrates raises concerns regarding interference with the physiological 
functions of BACE1 (Dislich and Lichtenthaler, 2012; Kuhn et al., 2012). The 
difficulties in developing potent drugs that can cross the BBB have now been over-
come and is reflected by that the increasing number of late preclinical and early clinical 
BACE1 directed inhibitors. The recent results from the first-time-in-man study with a 
BACE1 non-peptidic inhibitor showed good efficacy as both Aβ and sAPPβ were 
decreased (May et al., 2011). Unexpectedly, the study had to be halted since a mouse 
model showed retinal pathology upon long-term treatment. However, the effect was 
later proven to be unrelated of BACE1 inhibition, since the finding was recapitulated in 
BACE1 kock-out mice treated with the same compound (May et al., 2011). Similar to 
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γ-secretase, BACE1 is also subjected to immunization studies. Both active and passive 
vaccinations studies have reported to inhibit the enzyme in mice models (Atwal et al., 
2011; Chang et al., 2007; Zhou et al., 2011). Another strategy involving inhibition of 
BACE1 is to target its subcellular localization and indirectly reduce its processing 
activity. These drugs, such as bepridil and amiodarone, raise the membrane-proximal 
pH in the endosome above pH4.5, which is the optimum pH value for BACE1, and 
consequently decrease Aβ production (Mitterreiter et al., 2010).  
 
1.4.2.1.2 Inhibition and modulation of the γ-secretase complex 
The γ-secretase complex is an appealing drug target when the therapeutic strategy is to 
alter the metabolism of Aβ. It is directly involved in the Aβ formation and it also 
determines the pathogenic potential of Aβ. In 1995, the first compounds were reported 
that could inhibit γ-secretase activity. These compounds were of the peptide aldehyde-
type and the following years several peptidomimetic compounds were developed 
including; MW167, L-685,458, DAPT and helical peptides (Bihel et al., 2004; Das et 
al., 2003; Dovey et al., 2001; Shearman et al., 2000; Wolfe et al., 1998). Some of these 
compounds are substrate based, such as the helical peptides that contain the γ-secretase 
cleavage site of APP, and some are transition-state analogue inhibitors, such as L-
685,458 that only bind to the active site. Both these classes of compounds bind the 
NTF/CTF interface, but at different sites (Esler et al., 2000; Kornilova et al., 2005), 
consistent with the previous finding of an initial substrate-docking site (Beher et al., 
2003; Esler et al., 2002). Interestingly, competition studies with the helical peptides, L-
685,458 and DAPT, suggest that DAPT binds to a site distinct from the active site and 
the docking site (Morohashi et al., 2006) but with some overlap. Thus, DAPT may 
interact with the substrate transit-path from the docking site to the active site (Wolfe, 
2012). Early γ-secretase inhibitors (GSIs) have been very useful as chemical tools for 
characterizing the γ-secretase complex but have low potency. However, as more potent 
GSIs have been developed, their Aβ lowering abilities could be confirmed in transgenic 
mice models (Dovey et al., 2001; Lanz et al., 2004). Unfortunately, severe side effects 
such as gastrointestinal toxicity and immunosuppression due to interference with the 
Notch signaling pathway have also been discovered when treatment was performed for 
longer periods (2 weeks) (Searfoss et al., 2003; Wong et al., 2004). In accordance, side 
effects assigned blocked Notch signaling and worsening in cognition of treated as 
compared to placebo-treated patients, caused a recent large clinical phase III trial with 
the GSI semagacestat to be interrupted in August 2010, reviewed in (Imbimbo and 
Giardina, 2011; Wolfe, 2012). Since semagacestat has no substrate specificity, this was 
not unexpected and therefore current investigations attempt to find GSIs with a 
sufficient therapeutic window between APP and Notch processing. The first Notch-
sparing γ-secretase inhibitor Gleevec was reported in 2003. Gleevec is an abl kinase 
inhibitor, but the Aβ lowering properties are in an abl kinase-independent manner since 
the selective effect was retained in abl kinase knock-out cells (Netzer et al., 2003). 
Recently, a γ-secretase-activating-protein (GSAP) that is the target of Gleevec has been 
identified. GSAP was shown to regulate γ-secretase processing of APP but not Notch 
as Aβ levels were reduced during knock-down of GSAP in a transgenic mouse model 
without any observed Notch related side effects (He et al., 2010). Beyond Gleevec, the 
development of APP selective compounds has been extremely challenging (Lundkvist 
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and Naslund, 2007) and as a consequence only a few Notch-sparing GSIs with 2-≈190 
fold selectivity for APP over Notch have entered clinical trials. Examples of these 
include; Semagacestat from Lilly, BMS-708163 from Bristol-Myers-Squibb, PF-
3084014 from Pfizer, GSI-953 from Wyeth and ELND-006 from Elan. Except BMS-
708163, all compounds have been precluded further clinical development, probably due 
to mechanism-based toxicity as a result of impaired Notch signaling and other 
pathways discussed above (Gillman et al., 2010; Imbimbo and Giardina, 2011; Lanz et 
al., 2010; Mayer et al., 2008; Wolfe, 2012).  
 Given the challenge observed with γ-secretase inhibitors, alternative therapeutic 
strategies that spare Notch signaling while targeting γ-secretase mediated Aβ 
production are in progress. For instance, Notch inhibition is avoided using so called γ-
secretase modulators (GSMs). Typically, GSMs do not affect the overall rate of Notch, 
APP (ε and S3 cleavage) or ErbB4 processing (Kukar and Golde, 2008; Weggen et al., 
2001). However, by shifting the cleavage preference of the enzyme from producing the 
amyloid-prone Aβ42 variant to shorter and less toxic Aβ species, GSMs change the 
proportions of various forms of Aβ peptides (Weggen et al., 2001; Weggen et al., 
2003). The first GSMs, subsets of non-steroidal anti-inflammatory drugs (NSAIDs), 
such as sulindac sulfide and ibuprofen, were identified in 2001 (Weggen et al., 2001). 
The first GSM entering clinical trials was R-flurbiprofen from Myriad Genetics, 
showing promising effects in APP transgenic mice (Kukar et al., 2007). Since then, a 
number of compounds have reached or are approaching clinical trials, including E2212 
from Eisai, CHF5074 from Chiesi Farmaceutici, EVP-15962 from EnVivo 
Pharmaceuticals and NPG-328 from Neuro Genetic Pharmaceuticals (Imbimbo and 
Giardina, 2011). Unfortunately, R-flurbiprofen failed in phase III (Green et al., 2009), 
probably due to its low Aβ reducing efficacy and poor brain penetration, a feature 
likely shared with the other compounds. The last decade, many second-generation 
GSMs have brought improvement. These compounds are generally structurally distinct 
from the NSAID family and lack the acidic carboxyl group, associated with the NSAID 
family of GSMs. Importantly, many of these compounds display a much higher 
potency and a better BBB penetration, and do therefore lower CNS Aβ production 
much more efficiently compared to the early GSMs (Kounnas et al., 2010; Oehlrich et 
al., 2010; Portelius et al., 2010; Tomita and Iwatsubo, 2006). The binding site of GSMs 
is still under debate. Some studies associate NSAID-based GSMs with the APP-derived 
C99 peptides (Botev et al., 2011; Kukar et al., 2008; Richter et al., 2010), but other 
groups have challenged this implied substrate-targeting hypothesis (Barrett et al., 2011; 
Beel et al., 2009; Clarke et al., 2006; Page et al., 2010). However, during the last year, 
γ-secretase instead of APP has been identified as the principal target of second-
generation GSMs (Borgegard et al., 2012; Crump et al., 2011; Ebke et al., 2011; 
Jumpertz et al., 2012; Kounnas et al., 2010; Ohki et al., 2011). These studies include 
pull down of crosslinked photoprobes of the specific GSM, coupling of GSM to a solid 
support followed by affinity chromatography or autoradiography binding studies with 
tritium-labeled GSM. Some groups also performed competition experiments with GSIs 
and /or other GSMs in order to compare binding sites, and although some inconsistent 
data, the results suggest an allosteric mechanism targeting the enzyme (Borgegard et 
al., 2012; Ebke et al., 2011; Jumpertz et al., 2012; Ohki et al., 2011).  
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2 AIMS OF THE THESIS 
 
The proteolytic activity of γ-secretase is a key step in the pathogenesis of AD, since it 
is directly involved in Aβ formation and also determines the pathogenic potential of 
Aβ. A detailed knowledge about the γ-secretase complex will help to understand at 
least a part of the intricate mechanisms of the disease. Since γ-secretase mediates 
cleavage of many substrates involved in cell signaling, such as the Notch receptor, it 
is crucial to sustain these pathways when developing γ-secretase targeting drugs for 
the treatment of AD. Notch signaling, for instance is important for cell differentiation 
and proliferation processes in many tissues in adulthood, and several clinical trials 
with different γ-secretase inhibitors have resulted in adverse side effects which are 
probable due to impaired Notch signaling. (reviewed in (Imbimbo and Giardina, 
2011)). It is therefore very important to develop novel strategies to combat Aβ 
production via γ-secretase and other targets. In order to develop novel, effective and 
safe γ-secretase targeting strategies, including GSMs, additional knowledge about the 
mechanisms of γ-secretase processing is required. The general aim of this thesis was 
to learn more about the molecular basis of γ-secretase heterogeneous γ- and ε- 
cleavage activity and to characterize and identify differences between γ-secretase 
mediated APP and Notch processing by using genetic and pharmacological 
approaches.  
 
The specific aims of this thesis were: 
 
Paper I:  To examine how PS1 FAD mutations cause elevated Aβ42/Aβ40 ratio by 
investigating if they: i) induce an alteration in the membrane integration 
of PS1 TMDs, ii) influence structural changes in the catalytic site. 
 
Paper II:  To study the importance of the large hydrophilic loop of PS1 for γ-
secretase complex assembly and processing of APP and Notch. 
 
Paper III:  To investigate the role of the Nicastrin ectodomain for APP and Notch 
processing. 
 
Paper IV:  To characterize how first- and second- generation GSMs affect γ-
secretase processing of both APP and Notch by examining the modulation 
of Aβ, Nβ and NICD. 
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3 COMMENTS ON METHODOLOGIES 
 
Several methods and systems have been used during the course of this thesis project. In 
this section, benefits and limitations as well as similarities and differences concerning 
the different models and procedures will be described and discussed. Detailed 
descriptions of the techniques are found in the respective paper.  
 
3.1 MATERIALS 
Alzheimer disease is a complex multi-pathogenic disorder and is therefore challenging 
to mimic in a suitable model. Human post-mortem brain provides a valuable model for 
studying the disease state. However, it is only possible to obtain static information at a 
specific time point and is not reflecting the considerable changes that occur during the 
course of disease, which progresses over a long time period. Another limitation is the 
availability of human brain tissues and the often long post-mortem time that needs to be 
taken into account. Moreover, individual differences between brains can be large. One 
alternative to human material is to use animal models, which can be used for examining 
dynamic processes that will gain information about different stages of the disease. In 
addition, the post-mortem time can also be kept at a minimum. Unfortunately, no 
species, except humans, develop the disease and thus, there is no true animal model for 
AD, only transgenic models that mimic different aspects of the disorder. To study a 
specific process or signaling pathway, the use of cell culture is a very convenient 
model. The advantages are unlimited numbers, considerably lower individual 
differences than either human brains or animals and there are less ethical considerations 
about immortalised cell lines. Moreover, cells are susceptible to modifications such si-
RNA knock-down or over-expression of proteins and it is possible to study a 
mechanism of interest in a less complex and more controlled environment. However, 
due to their simplified nature and that they have been removed from their physiological 
context; caution must be taken into account when making comparisons between cellular 
observation and a human disease. 
 
3.1.1 Cell culture 
All studies in this thesis are mainly based on immortalized cell lines and includes; 
blastocyst-derived embryonic stem cells deficient for PS1 and PS2 (BD8 cells) (Paper 
I and II), mouse embryonic fribroblats lacking Nicastrin (Nct-/- MEF) (Paper III) or 
human embryonic kidney (HEK) cells over-expressing either APP with the swedish 
mutation or Notch∆E (Paper IV). Cell lines deficient of the protein of interest have the 
advantage of minimizing the influence of endogenous protein and thereby simplifying 
the interpretation of the result and the effect of over-expressed protein. However, 
regarding PS1 FAD mutations (Paper I), this model does not totally reflect a 
pathogenic state, which includes a wild type allele and one mutated allele. The studies 
include both transient and stable over-expression of proteins and both methods have 
their benefits and disadvantages. Transient expression is a rapid method to express and 
analyze the protein of interest but since the cDNA is not inserted into the cell genome, 
it will eventually be degraded. To ensure equal transfection efficiency in the transient 
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experiments, co-transfection of GFP or a CMV-β-gal vector was used. Stable 
expression of protein ensures long-term and reproducible protein levels. Nevertheless, 
for the analysis of multiple mutations it is important to select clones with similar 
expression levels and one drawback may include decreased expression levels over time, 
even though the cells are kept under antibiotic selection pressure. Further, long time 
over-expression of proteins exposes the cells to stress, especially if multiple proteins 
are over-expressed, which is important to consider when physiological interpretations 
of results from such cells are made. However, for some methods the use of stably over-
expressing proteins is required in order to be able to detect the peptides of interest.  
 
3.1.2 Animals 
In Paper I, the membrane integration of PS1 TMDs was investigated using dog 
pancreas rough microsomes in order to get glycosylated samples. The microsomes were 
a kind gift from Prof. Arthur E. Johnson at the Texas A&M University, USA and 
ethical permission of the animal tissue was approved in accordance with Animal 
Welfare Regulations CFR9, Ch. 1, A,2.31 (d)(2)(5) by the University IACUC 
committee. For examining in vivo potency as well as binding site of the AZ4126 
compound (Paper IV), C57BL/6 mice (Harlan Laboratories) and sagital brain sections 
from rats were used, respectively. All animal experiments were performed in 
accordance with relevant guidelines and regulations provided by the Swedish Board of 
Agriculture and the ethical permission was provided by the Stockholm Södra Animal 
Research Ethical Board. 
 
3.1.3 cDNA constructs 
Several cDNA constructs have been created during this thesis project. Most constructs 
include single or multiple amino acid changes in PS1 or Nicastrin (Paper I and III) 
and were generated with wild type DNA as a template by using the QuikChange Site-
Directed Mutagenesis or QuikChange Multi Site-Directed Mutagenesis (Strategene), 
respectively. The PS1 TMD segments (Paper I) and PS1∆exon 10 construct (Paper II) 
were created using PCR with designated primers and then cloned into desired vectors 
using conventional cloning techniques. The N-terminal truncated PS1 CTF constructs 
and introduction of glycosylation acceptor sites on PS1wt and PS1∆exon 10 (Paper II) 
were performed using designated primers according to Quick Change mutagenesis 
protocol (Stratagene). The DNA sequence of all constructs was verified using the 
BigDye® Terminator Version 3.1 Cycle Sequencing kit (Applied Biosystems).  
 
3.2 ANALYSIS OF γ-SECRETASE COMPLEX 
In this thesis, six methods have been used to study the γ-secretase complex. The 
techniques were used to cover various aspects of the enzyme and therefore are quite 
different in their procedures. Though, all methods have in common that all end 
products of the methods, except the radioligand experiments, were analyzed by 
immunoblottning using SDS-PAGE. SDS-PAGE is used to separate proteins according 
to size and the strong detergent SDS is used to reduce the samples, destroying almost 
all protein interactions. After treatment with antibodies of interest, the proteins are 
detected using chemoluminescence either by X-ray film or CCD camera. Traditionally, 
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X-ray film has been used to detect a chemoluminescent signals and have a high 
sensitivity. However, as it is hard to control when the film reach saturation, the risk of 
getting over-exposed images can be a problem. The advantage with a CCD camera is 
its large dynamic range and the possibility to optimize exposure times during the 
detection to avoid signal saturation. Therefore, images that will be quantified are 
preferably exposed in a CCD camera but if X-ray films are used, extra caution is 
needed to avoid saturated bands. 
 The membrane integration assay of PS1 FAD mutations (Paper I) and topology 
study of the PS1∆exon 10 molecule (Paper II) are techniques used to investigate how 
modifications in PS1 are affecting its integration into the membrane. Both methods are 
based on the introduction of glycosylation acceptor sites that get glycosylated if they 
are present in the lumen. As a control, Endoglycosidase H treatment, which 
deglycosylate the samples were included. Another way to study how alterations affect a 
protein is to evaluate its stability and half-life using Cycloheximide treatment. 
Cycloheximide inhibits protein synthesis by interfering with the translation step, 
blocking the translation of mRNA into protein, and is a convenient method to observe 
the half-life of a protein without interference from transcription or translation. This 
treatment was used to study the stability of the PS1∆exon 10 molecule and the most N-
terminal truncated CTF fragment, CTF start375 (Paper II) as well as Nicastrin 
containing the C1, C2, C3 or C4 mutants (Paper III). The stability of the altered 
proteins was compared to the wild type proteins. 
 Co-immunoprecipitation is a commonly used method to examine physiological 
protein-protein interactions. In this thesis, the method was used to study if alterations in 
either PS (Paper II) or Nicastrin (Paper III) decrease or disrupt the interactions to the 
other components in the γ-secretase complex. It is important to maintain stable 
interactions throughout the procedure in order to detect the bound proteins and since 
protein-protein interactions can be sensitive to detergents, analyzing membrane proteins 
can be challenging. Therefore, a mild detergent (1% CHAPSO) which retains γ-
secretase activity (Franberg et al., 2007) was used for studying the interaction within 
the γ-secretase complex. The interactions between γ-secretase components can also be 
examined using an affinity capture approach. Here, membrane-prepared γ-secretase 
complexes were incubated with the L-685,458 coupled to a cleavable biotin group 
(GCB) followed by incubation with streptavidin beads to capture the active γ-secretase 
complexes. This method addresses if alterations in γ-secretase components influence 
structural changes in the catalytic site. Since L-685,458 is a transition state analogue 
inhibitor, fewer active γ-secretase complexes would be pulled down compared to wild 
type if the catalytic site is affected. Affinity capture was used to investigate if changes 
in PS (Paper I and II) or Nicastrin (Paper III) affect the catalytic site. As the L-
685,458-GCB molecule has been modified, it is important to confirm that it has similar 
characteristics as the L-685,458 inhibitor. L-685,458-GCB has indeed previously been 
shown to block Aβ production with a similar IC50 as L-685,458 (Teranishi et al., 2009). 
Both affinity capture and co-immunoprecipitation examine interactions between γ-
secretase components. However, in contrast to affinity capture that only detects 
interactions in active complexes, co-immunoprecipitation also detects mature inactive 
complexes as well as sub-complexes. It is important to secure the specificity of the 
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detected protein interactions when using pull-down techniques. For affinity capture, L-
685,458 was added prior to the biotinylated inhibitor as a negative control and co-
immunoprecipitation was also performed with only pre-serum that contains no specific 
antibody. 
 To understand how different molecules interact and affect the γ-secretase 
complex, binding studies in combination with displacement experiments can be 
performed. In Paper IV, radioligand displacement binding experiment with an 
established tritiated second-generation GSM ([3H]AZ8349) as tracer (Borgegard et al., 
2012) was performed to confirm that the novel AZ4126 compound belongs to second-
generation GSMs. An alternative to radioligand experiments includes photo-affinity 
labeling studies, which can be performed on living cells. However, drawbacks with that 
alternative include possible steric interference of the photo-probe to the binding site and 
cellular toxicity upon cross-linking with UV-light.  
 
3.3 DETECTION AND QUANTIFICATION OF Aβ AND Nβ 
To analyze Aβ production, three methods were used; Meso Scale Discovery (MSD) 
technology (Paper I-IV), Enzyme-linked immunosorbent assay (ELISA) (Paper IV) 
and Immunoprecipitation followed by matrix-associated laser desorption ionization- 
time of flight mass spectrometry (IP-MALDI-TOF MS) (Paper IV). Nβ was also 
detected using IP-MALDI-TOF MS and the identification of Nβ was confirmed by 
tandem mass spectrometry (MS/MS) using MALDI-TOF/TOF (Paper IV).  
MSD technology and ELISA are very similar in their quantification of an 
antigen, since both are based on a capture and a detection antibody. However, the MSD 
technology uses ruthenylated-detection antibodies (SULFO-TAG™) that are activated 
by electricity, in contrast to the more conventional ELISA using detection antibodies 
coupled to an enzyme, which upon addition of substrate converts it to colour or a 
fluorescent signal. An advantage with MSD is the high signal-to-noise ratio, since the 
activation by electricity is decoupled from the electrochemoluminescence signal and 
also multiple excitation cycles enhances the signal. Moreover, some MSD plates have 
MULTI-SPOT®, allowing detection of more peptides in one well under exact same 
conditions. However, MSD technology requires a specific expensive instrument, in 
contrast to ELISA that is measured in a normal absorbance or fluorescent detecting 
plate-reader. All sandwich immunoassays have two options for the specific antibody, 
either as capture or detection antibody. It is preferable to use the specific antibody as 
the capturing antibody, because if a general antibody that recognizes all isoforms of a 
peptide is used to capture the peptides, high abundant isoforms may occupy most sites, 
resulting in low or non-detection of species present in low levels.  
By using IP-MALDI-TOF, specific peptides and importantly multiple isoforms 
of a peptide can be identified/characterized and quantified. Here, the peptides are 
converted into gas phase ions and then separated according to their mass-to-charge 
ratios (m/z). Benefits with MALDI-TOF are that it is a very sensitive method, offer 
high resolution and mass accuracy and the samples are examined relatively fast. 
Moreover, the technique is quite robust, allowing comparatively high concentrations 
of salts, buffers and other contaminations in the sample. Unfortunately, it is not 
possible to couple a liquid chromatography to a MALDI-TOF (Portelius et al., 2008). 
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Information about the primary structure, i.e. amino acid sequence, of a peptide or 
protein of interest can be obtained by using MS/MS. Peptides of a specific m/z are 
selected and isolated from all different peptides entering the mass spectrometer. Next, 
the peptides are fragmented and analyzed in the mass analyzer. 
 
3.4 DETECTION OF INTRACELLULAR DOMAINS 
The detection of ICDs was investigated with a Luciferase-Reporter Gene Assay and the 
ImageXpress platform that is based on immunocytochemistry. Both AICD and NICD 
formation was studied with Luciferase-Reporter Gene Assay (Paper I-III). γ-Secretase 
mediated cleavage of C99 and Notch∆E, a truncated form of the Notch1 receptor 
resembling S2-cleaved Notch, is analyzed with two hybrid constructs containing an 
incorporated GVP domain. During γ-secretase cleavage, the ICDs with the GVP moiety 
translocate to the nucleus due to a a nuclear localization signal in the GVP domain. The 
luciferase-reporter gene (MH100) is activated through the specific binding of GVP to 
the UAS promoter, thereby enabling an exclusive signal by the GVP domain. The 
Luciferase-Reporter Gene Assay is both very sensitive and has a high specificity 
(Karlstrom et al., 2002). In addition, a benefit with this system is that it makes it 
possible to study the processing of APP and Notch in a similar experimental setup, 
under the same conditions. Often, APP and Notch processing is investigated in different 
system, making it harder to evaluate disparities correctly. However, the method is 
based on the incorporation of a non-physiologic domain into the ICD that interferes 
with their stability, which needs to be considered. On the other hand, non-manipulated 
AICD is very unstable, therefore most methods used to investigate AICD involve some 
kind of manipulation of its stability. Moreover, the results from this technique are 
compared to the processing of wild type protein under the same conditions, therefore 
considering relative changes. 
 Modulation of S3-cleaved NICD was also determined by immunocytochemistry 
using ImageXpress (Paper IV). The system is based on conventional 
immunocytochemistry but in a 384-well format, having the advantage of allowing 
massive data collection under the same conditions during one experiment. Therefore, 
dose-response experiments with AZ GSMs, L-685,458 and vehicle for two antibodies, 
one recognizing total NICD and the other NICD starting specifically at position V1744 
(V1744-NICD), could be performed at the same time. This enables robust data 
regarding modulation of NICD, by relating V1744-NICD to total NICD. However, the 
specificity of the method is still dependent on the specificity of the antibodies, but 
importantly, L-685,458 inhibited V1744-NICD formation with similar potency 
(IC50Val1744=10.0nM) as previously determined for its effect on total NICD formation 
(IC50C20= 6.0nM (Borgegard et al., 2012)). 
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Figure 7. Schematic illustration of the genetic alterations used in the thesis. A) The localization of 
the PS1 FAD mutations in Paper I. Picture modified from http://www.molgen.ua.ac.be/admutations/  
B) Schematic presentation of PS1wt, PS1 ∆exon 10 and the CTF construct lacking exon10, CTF 
start 375 in Paper II. C) The localization of cysteine residues that are mutated to serines, C195S 
(C1), C213S (C2), C230S (C3), and C248S (C4) in the Nicastrin protein in Paper III. 
4 RESULTS AND DISCUSSION 
In this section, the main findings from Paper I-IV are summarized and discussed based 
on the aims of the thesis. To improve the understanding and support the discussion, 
some figures from the individual papers are also presented. A more detailed discussion 
of the results and all figures are found in the specific papers.  
 
4.1 THE γ-SECTRETASE COMPLEX CAN BE SUBJECTED TO MANY 
GENETIC ALTERATIONS AND STILL BE PARTIALLY FUNCTIONAL  
In order to gain more knowledge about the mechanisms of γ-secretase processing, to 
differentiate between γ-secretase mediated APP and Notch processing as well as to 
gain a better understanding of the molecular basis of the heterogeneous γ- and ε- 
cleavage activity, both genetic and pharmacological alterations were applied to study 
γ-secretase in this thesis. Different techniques were used to assess the γ-secretase 
complex in the papers, although some methods have been used in several studies. 
Interestingly, one general finding in the thesis is that; the γ-secretase complex can be 
subjected to many genetic alterations and still be partially functional, although in 
some cases very vulnerable, when 31 FAD mutations (Paper I), the ∆exon 10 
molecule and N-terminal truncated CTF variants of PS1 (Paper II) as well as four 
Nicastrin mutations (Paper III) were examined, schematically shown in Figure 7.  
 The mechanism(s) by which PS1 FAD mutations cause an elevated Aβ42/Aβ40 
ratio is still incompletely understood, but that a conformational change in PS1 is 
responsible for the Aβ phenotype is one proposed mechanism. In Paper I, a membrane 
integration assay in an in vitro transcription/translation system based on N-linked 
glycosylation was used to evaluate if FAD mutations affect the integration of their 
respective transmembrane domains. Most mutations did not affect membrane 
integration, but six mutations were identified that either increased or decreased the 
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membrane integration with more than 20% compared to wild-type PS1. Very 
interestingly, all PS1 FAD mutations that changed the TMD membrane integration are 
located in hydrophobic domains around the catalytic site (TMD6, H7 and TMD7), 
suggesting that this area is particularly vulnerable to modifications. In contrast, the 
PS1∆exon 10 molecule, lacking the large hydrophilic loop between TMD 6 and 7 of 
PS1 was shown to have unaltered membrane topology (Paper II). In addition, co-
immunoprecipitation studies showed that PS1∆exon 10 interacts with Nicastrin, Aph-1 
and Pen-2. Moreover, affinity capture confirmed that an active site directed transition 
state analogue inhibitor of γ-secretase can bind the active site of the PS1∆exon 10 
molecule and pull down PS1-NTF. This demonstrates that PS1∆exon 10 can assemble 
into a functional and active γ-secretase complex. Strikingly, not only mutations in PS1 
can produce active γ-secretase complexes, three out of four Nicastrin cysteine 
mutations could interact with the other components and form active complexes, 
although the C3 mutant gave rise to fewer active complexes (Paper III). The fourth 
mutation, C4 failed to interact with any other component than Aph-1, which has been 
shown previously (Shirotani et al., 2004a) and explains its lack of activity on both APP 
and Notch. Moreover, neither Nicastrin cysteine mutations nor the exon 10 deletion in 
PS1 impaired protein stability as observed by cycloheximide-treated cells (Paper II 
and III). However, even though the NTF of PS1∆exon 10 is stable, apparent lower 
levels of PS1∆exon 10 NTF were observed, and the endoproteolytic event was found to 
be 10-fold decreased compared to PS1wt (Paper II). It has previously been shown that 
it is possible to reconstitute γ-secretase activity in the absence of PS endoproteolysis, 
by co-expressing PS NTF and CTF encoding constructs (Laudon et al., 2004). This 
experimental setup enabled us to study NTF levels under conditions bypassing 
endoproteolysis. By generating a PS1 CTF construct lacking exon 10, denoted CTF 
start 375, and co-expressing it with PS1 NTFwt, we observed lower levels of NTFwt in 
the presence of CTF start 375 than in the presence of CTFwt. This indicates that the 
loop, apart from endoproteolysis, is also important for complex formation, since we 
still noticed lowered NTFwt levels even when bypassing PS endoproteolysis. 
 Although PS1 can form active complexes in the absence of the large 
hydrophilic loop, we observed a tendency of decreased binding to the transition state 
analogue inhibitor for PS1∆exon10 compared to PS1wt. Interestingly, the same 
phenomenon was also observed when six PS1 FAD mutations as well as the Nicastrin 
mutant C3 were subjected to affinity capture by the transition state analogue inhibitor 
(Paper I and III). This suggests a conformational change of the active site in these 
molecules. Indeed, both genetic and pharmacological manipulations, which increase the 
Aβ42/Aβ40 ratio, are associated with a uniformly conformational change in the 
catalytic site of PS1 (Berezovska et al., 2005; Lleo et al., 2004; Uemura et al., 2009). 
Moreover, Kornilova et al. have shown that certain PS FAD mutations have reduced 
photo-labeling by a transition-state analogue (Kornilova et al., 2005). Combined, all 
experiments indicate that γ-secretase in general can form partially functional complexes 
although it is subjected to many different genetic alterations. However, the amount of 
active complexes, and more importantly, the properties regarding their activity differs 
extensively, as described in the next sections.  
 
   39 
Figure 8. Impairments in the Aβ product lines, as 
proposed by Chavez-Gytierrez et al. 2012. 
4.2 THE RELATIONSHIP BETWEEN ε- AND γ-CLEAVAGE OF APP 
One of the aims of this thesis was to understand the relationship between the 
heterogeneous γ- and ε- cleavage activity on a molecular basis. Consequently, we 
wanted to compare the Aβ-profile from the six out of 31 investigated FAD mutations 
that changed the membrane integration of their respective TMDs, with mutations that 
did not affect membrane integration (Paper I). In total 12 mutations were examined. 
Interestingly, five mutations that did not alter the membrane integration stood out, 
either by having no effect or by causing a very high increase in the Aβ42/Aβ40 ratio 
(>4 compared to wild-type). The four mutations; I143T, L166P, ∆exon9 and G384A, 
which resulted in a very high Aβ42/Aβ40 ratio also caused a pronounced decrease in 
Aβ40. The same phenomenon was observed for the L392P mutation, which caused a 
lower but still significant increase in the Aβ42/Aβ40 ratio (>3). Besides these 
similarities, we could also observed some differences in the way these mutants affected 
APP processing. For instance, while the I143T, L166P, ∆exon9 and G384A mutations 
caused a decrease in AICD formation, the L392P mutation did not. The mechanism 
between this discrepancy is not known, but recent discoveries by Chavez-Gytierrez and 
colleagues may shed some light on the underneath molecular mechanism, see Figure 8. 
By taking on a different approach to explore the effect of FAD mutations on Aβ 
production, Chavez-Gytierrez and colleagues found two different mechanisms by 
which FAD mutations could cause 
an increased Aβ42/Aβ40 ratio. 
Either the mutation interferes with 
the processing at the ε-site of the 
predominant Aβ40 product line 
(AICD50-99 + Aβ49>>Aβ40), 
causing a net decrease in Aβ40, 
and/or the mutation impairs the 
fourth cleavage in any of the two 
product lines, resulting in either 
decreased Aβ40 or increased Aβ42 
levels (Chavez-Gutierrez et al., 2012). Based on these findings, impaired initial ε-
cleavage of the predominant AICD50-99 + Aβ49>>Aβ40 product line, would explain the 
low AICD generation and thus reduced Aβ40 production that we observed for the 
I143T, L166P, ∆exon9 and G384A mutations. For the L392P mutation, which 
possessed intact AICD formation, damage to the fourth cleavage could explain the 
obtained results. Either the mutation caused a decrease in the Aβ43>Aβ40-cleavage 
reaction, leading to lower Aβ40 levels or, alternatively, a decrease in the Aβ42>Aβ38-
cleavage, resulting in increased levels of Aβ42. The former mechanism appears most 
likely for the L392P mutation since it caused a selective decrease in Aβ40 production. 
For the G384A mutation, which caused a dramatic increase in Aβ42 levels, the latter 
mechanism makes most sense. 
 The product line hypothesis is also to some extent applicable to explain the 
results obtained from the studies using artificial mutations in nicastrin (Paper III) and 
PS1 (Paper II). The nicastrin cysteine mutations; C1, C2 and C3 all displayed a 
concomitantly reduction of AICD and Aβ40 that might reflect an impairment at the ε-
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cleavage of the predominant AICD50-99 + Aβ49>>Aβ40 product line. The data obtained 
from Paper II, where we analyzed the impact of the large hydrophilic loop of PS1 on 
γ-secretase activity, appear more complex. The absence of the loop region resulted in a 
decrease in total Aβ levels without affecting AICD generation, suggesting that the loop 
region is important for the γ-secretase activity once processing at the ε-cleavage site has 
already been initiated. Besides these findings, the ∆exon10 mutant also gave rise to a 
different Aβ pattern, where the formation of the shorter Aβ38, Aβ39 and Aβ40 species 
were reduced to a much larger extent compared to Aβ42. These observations are not 
easily explained using the product line hypothesis, but may reflect a general partial loss 
of function in γ-secretase activity where the Aβ42 product line is impaired to a lesser 
extent compared to the Aβ40 product line. In our efforts to further understand the role 
of the loop region in regulating Aβ production, we generated partial deletions starting 
from the N-terminal towards the C-terminal end of the loop region of PS1 CTF, and co-
expressed the different deletions with PS1 NTFwt in PS deficient cells. These deletions 
resulted in a gradual loss of all Aβ peptides. Interestingly, however, removal of the 
amino acid closest to the C-terminal end of the loop did not further impair Aβ42 
production, but the generation of Aβ38, Aβ39 and Aβ40 was dramatically decreased. 
The differential effect on Aβ42 versus shorter Aβ peptides would not be compatible 
with a general loss of function of γ-secretase activity. Rather, the effect of the last C-
terminal amino acids of the loop would fit with a selective impairment at the fourth 
cleavage event of the product line mechanism, resulting in unaltered Aβ42 levels and 
reduced levels of Aβ38 and Aβ40. Interestingly, the impact of deleting the loop region 
on Aβ production resembles the Aβ phenotype of many FAD-linked PS1 mutants 
(Paper I, (Bentahir et al., 2006; Chavez-Gutierrez et al., 2012; Kumar-Singh et al., 
2006)). This Aβ-phenotype translates to an increased amyloid deposition in both FAD 
patients and transgenic models expressing FAD-linked PS. The FAD-like Aβ 
phenotype of PS1∆exon 10 also causes an enhanced amyloidosis in transgenic mice, as 
recently demonstrated by Deng et al. (Deng et al., 2006). Although the removal of 
∆exon 10 results in an Aβ phenotype similar to many FAD mutants, no FAD causing 
mutation has so far been identified in this region. Moreover, the similarity between the 
Aβ profile of the PS1 ∆exon10 molecule and many FAD mutations, combined with the 
fact that many mutations at different loci of the PS gene result in FAD, suggest that 
minor structural alterations in PS have a major impact on some specific cleavage 
events. This results in the detrimental imbalance in Aβ40 and Aβ42 production. Basi 
and colleagues have made a very similar observation. In an effort to identifying amino 
acids critical for the pharmacology of different γ-secretase inhibitors, they also found 
that many artificial mutants cause a more severe loss of shorter Aβ variants compared 
to Aβ42 (Zhao et al., 2008). 
A drawback of the hypothesis with impairments in the Aβ product lines and the 
original tri-/tetra-peptide-rule, is that they do not totally differentiate between the 
production of Aβ37, Aβ38 and Aβ39. Takami et al., as well as Chavez-Gytierrez and 
colleagues, associate Aβ38 with the Aβ48>>Aβ42 product line (Chavez-Gutierrez et 
al., 2012; Takami et al., 2009) and Aβ37 is assumed to be generated from Aβ40, but it 
has not been detected in the mentioned studies. Moreover, if a strict tri-peptide rule 
should apply, Aβ39 and not Aβ38 should be generated from Aβ42. However, Takami 
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Figure 9. Aβ peak distribution under the influence of A) first- and B) second-generation GSMs, 
examined by IP-MALDI-TOF. Each Aβ peak is plotted as a percentage of total Aβ (i.e. the sum of 
Aβ37-42). 
and co-workers observed no generation of Aβ39 from Aβ42, only Aβ38 (Takami et al., 
2009). The disparities may also reflect on the original α-helical model, which 
demonstrates that C99 adopts an α-helical structure, where 3.6 residues are needed to 
complete one turn (Lichtenthaler et al., 1999). Therefore, γ-cleavage cannot always 
occour every third residue and must sometime be compensated with cleavage after four 
residues, which would explain the conversion of Aβ42 to Aβ38. This is also in line with 
reports showing that first generation GSMs of the NSAID class modulate γ-secretase 
activity by shifting the amino acid cleavage from Aβ position 42 to 38 (Eriksen et al., 
2003; Weggen et al., 2001). However, it is more difficult to explain the pharmacology 
of the second generation GSMs in Paper IV, which has a more diverse effect on Aβ 
peptides. Here, antibody pull-down followed by MALDI-TOF analysis of Aβ peptides 
was used to study the pharmacological profile of two first- and two second-generation 
GSMs, as shown in Figure 9. Both common features but also differences were found. 
First generation GSMs; R-flurbiprofen and sulindac sulfide gave rise to a clear relative 
decrease in Aβ42 levels and concomitantly elevated Aβ38 levels. In contrast, treatment 
of both second generation GSMs; AZ1136 and AZ4126 resulted in a very potent 
reduction in both Aβ42 and Aβ40, consistent with the behavior of second-generation 
GSMs (Kounnas et al., 2010), and a corresponding increase in Aβ37. These data 
indicate that these different classes of GSM compounds modulate Aβ production 
through different mechanisms. Moreover, when treating cells with R-flurbiprofen and 
sulindac sulfide their pharmacological profiles revealed disparities; R-flurbiprofen 
primarily increased Aβ37, while sulindac sulfide reduced Aβ39. We also found that the 
relative levels of Aβ39 were elevated after AZ1136 treatment whereas AZ4126 caused 
an increase in Aβ38. Thus, besides the differences in Aβ modulation between the first- 
and second-generation GSMs, clear differences are found within each class of GSMs 
with regard to Aβ modulation. In summary, the Aβ product line hypothesis could 
explain the complex nature of Aβ production during normal conditions, in disease and 
during pharmacological manipulation in a very elegant manner, but additional 
experiments are needed to fully explain the ethiology of all commonly expressed Aβ 
peptides during different conditions. 
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4.3 MODULATION OF γ-SECRETASE PROCESSING OF APP AND 
NOTCH 
To develop and evaluate tolerably Notch-sparing compounds, including γ-secretase 
modulators, it is important to understand and characterize differences between γ-
secretase mediated APP and Notch processing. Parts of the DAP-domain in the 
Nicastrin ectodomain show similarities to the aminopeptidase and transferrin receptor 
superfamily, spawning the idea that Nicastrin might function as a receptor. However, 
since studies have reported contradictory results regarding the proposed substrate 
receptor-like role for Nicastrin (Chavez-Gutierrez et al., 2008; Dries et al., 2009; 
Shah et al., 2005), it remains unclear if Nicastrin is involved in substrate recognition 
or not. Interestingly, upstream to the DAP-domain, there are four evenly spaced 
cysteine residues (at position 195, 213, 230, and 248) that are conserved between 
human, mouse, Drosophila and C. elegans. Since cysteine residues in general are 
involved in protein confirmation and interaction, we wanted to examine the role of 
these conserved cysteine residues regarding their function in the γ-secretase complex. 
We found that two mutants of Nicastrin, C213S (C2) and C230S (C3), differentially 
affected APP and Notch processing (Paper III). While both the formation of Aβ and 
AICD was decreased, the production of NICD was maintained on a high level. This is 
to our knowledge the first study describing single amino acid residues in a non-PS γ-
secretase component which, when mutated, have a differential effect on the 
processing of different γ-secretase substrates. (Tolia et al., 2006; Walker et al., 2006; 
Yamasaki et al., 2006). Notably, C3 caused low levels of active γ-secretase 
complexes and also had less mature Nicastrin, indicating that the residual γ-secretase 
activity was sufficient to process Notch but not APP to the same extent. This is in line 
with a previous study, showing that deleted forms of Nicastrin (∆312–340 and ∆312–
369) only gave rise to minor disturbances in NICD signaling, despite the absence of 
mature Nicastrin (Chen et al., 2001). Furthermore, glycosylation of Nicastrin has 
previously been demonstrated not to be essential for γ-secretase assembly or γ-
secretase activity (Herreman et al., 2003; Shirotani et al., 2003). Nevertheless, the 
presence of a mature form of Nicastrin seems to be important for proper processing of 
APP. For example, C3 may induce a conformational alteration in Nicastrin, altering 
the whole γ-secretase complex so that immature Nicastrin could be part of the active 
complex, and thereby favoring Notch processing. Alternatively, the C2 and C3 
mutations could lead to a change in subcellular localization of the γ-secretase 
complex, favoring expression at the plasma membrane and thus explain the 
differential processing of APP and Notch. Indeed, APP processing can be influenced 
by targeting Nicastrin to different subcellular compartments (Morais et al., 2008). 
 We also investigated the effect of first- and second-generations GSMs on Nβ 
production, as shown in Figure 10 (Paper IV). Since both the first and second 
generation GSMs appear selective for Aβ modulation and do not appear to affect total 
Aβ formation, we were curious to learn whether Nβ would be modulated in a similar 
manner as Aβ and whether the specificity of the Notch S3 cleavage would be affected 
by different GSMs. Antibody pull-down followed by MALDI-TOF analysis of Nβ 
peptides revealed that both AZ1136 and AZ4126, but neither R-flurbiprofen nor 
sulindac sulfide, affected Nβ production. Similar to their effect on Aβ40 and Aβ42, 
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Figure 10. Aβ and Nβ peak distribution under the influence of second-generation GSMs, 
examined by IP-MALDI-TOF. A) Aβ distribution, each Aβ peak is plotted as a percentage of total 
Aβ (i.e. the sum of Aβ37-42). B) Nβ distribution, each F-Nβ peak is plotted as a percentage of total 
F-Nβ (i.e. the sum of F-Nβ16-25). 
AZ1136 and AZ4126 reduce both F-Nβ24 and F-Nβ25, but the relative effects are not 
as discriminating. Strikingly, even though AZ4126 decreases Aβ40 and Aβ42 
approximately twice as much as AZ1136 at their respective tested concentration, both 
compounds appear to have the same efficacy in reducing F-Nβ24 and F-Nβ25. Most 
of the shorter F-Nβ peptides were unaltered by both AZ GSMs but AZ1136 treatment 
slightly increased F-Nβ18 and in contrast F-Nβ21 was increased by AZ4126. Thus, 
the compounds do not affect the same shorter F-Nβ peptides, in contrast to their very 
clear relative elevation of Aβ37. However, it seems like AZ1136 and AZ4126 share a 
general pharmacological profile concerning APP and Notch processing, i.e. a 
decrease in the longer Aβ and F-Nβ peptides (Aβ40/Aβ42 and F-Nβ24/F-Nβ25) and 
an elevation of some of the shorter species. Nevertheless, AZ GSMs exhibit 
differences regarding which peptides are being modulated and the efficacy of the 
process. γ-Secretase-mediated Notch signaling through NICD formation is an 
extremely important event. Thus, identifying GSMs that do not affect NICD signaling 
is a key step when developing safe AD therapeutics. GSMs are compounds that are 
known to spare Notch signaling since they do not affect total NICD levels. However, 
it may not be only the total amount of NICD generated that ought to be considered, 
but also the specificity of the γ-secretase cleavage event at the S3 site. Importantly, a 
recent study showed that there are two physiological forms of NICD with different 
stability due to variations in their N-terminus, leading to disparities in their signaling 
intensities (Tagami et al., 2008). Therefore, we analyzed the modulatory effect of 
second-generation GSMs on the S3 cleavage of Notch. By using 
immunocytochemistry experiments, we could not find any evidence that would 
suggest that AZ1136 and AZ4126 modulate Notch S3 cleavage, suggesting that the 
AZ GSMs are selective for S4 cleavage modulation. Therefore, these data suggest 
that it is possible to generate γ-secretase-targeting GSMs that are pre-selective for Aβ 
over Nβ production without affecting NICD formation, a feature that may be 
important in the development of GSMs for chronic treatment in AD.  
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
The work of this thesis has focused on how genetic (Paper I-III) and 
pharmacological (Paper IV) modulations affect the γ-secretase complex. During the 
last decade the mechanism of γ-secretase processing has started to emerge. 
Nevertheless, the growing list of γ-secretase substrates and severe side effects of GSIs 
in clinical trials highlights the needs of considering the importance of these pathways 
when targeting the γ-secretase complex. Further, a detailed knowledge on how γ-
secretase activity is regulated still remains elusive. 
In this thesis, it was found that the γ-secretase complex can be subjected to many 
genetic alterations and still be functional, although to different extents. Moreover, only 
six out of 31 PS1 FAD mutations changed TMD membrane integration and they were 
localized in hydrophobic domains around the catalytic site, TMD6, H7 and TMD7 
(Paper I). In contrast, all tested FAD mutations affected the catalytic site of γ-
secretase, the same were also observed for the PS1 ∆exon10 molecule and the Nicastrin 
mutation C3 (Paper II-III). This suggests that the catalytic site is vulnerable to genetic 
alterations but structural changes of the active site often allow the enzyme to be 
partially functional. This is in line with that three out of four Nicastrin cysteine 
mutations and PS1∆exon 10 can assemble into a functional and active γ-secretase 
complex but that the Nicastrin cysteine mutations; C1, C2 and C3 have a concomitantly 
reduction of AICD and Aβ40. However, the absence of the loop region in PS1 affects 
Aβ formation but not AICD generation (Paper II), implicating that it differentially 
regulates γ-secretase activity between the γ- and the ε-site. Moreover, the loop region is 
also important for regulating Aβ production, since the ∆exon10 molecule exhibits a 
large reduction in the formation of shorter Aβ38, Aβ39 and Aβ40 species as well as 
secreted total Aβ. Importantly, the generation of Aβ42 is only partially impaired under 
the same conditions. In addition, removal of the amino acids closest to the C-terminal 
part of the loop did not further impair Aβ42 production but the generation of Aβ38, 
Aβ39 and Aβ40 was dramatically decreased. Therefore, it appears that these amino 
acids are more responsible for production of shorter Aβ peptides than for Aβ42. This 
phenotype resembles the Aβ generation pattern of FAD mutations in Paper I and these 
features fit very well with a recent report on how FAD mutations affect the Aβ product 
lines (Chavez-Gutierrez et al., 2012). 
In Paper IV, GSM treatment showed that different classes of GSM compounds 
modulate Aβ production through different mechanisms. Importantly, besides the 
differences in Aβ modulation between the first- and second-generation GSMs, clear 
differences were also found within each class of GSMs with regard to Aβ modulation. 
Moreover, neither R-flurbiprofen nor sulindac sulfide affected Nβ production. 
Strikingly, AZ1136 and AZ4126 shared a general pharmacological profile concerning 
APP and Notch processing, although they exhibited differences regarding which 
peptides were modulated and the efficacy of the processing. Moreover, these 
compounds caused no modulation of Notch S3 cleavage, indicating that the AZ GSMs 
are selective for S4 cleavage modulation. Therefore it is possible to generate γ-
secretase-targeting GSMs that are pre-selective for Aβ over Nβ production without 
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affecting NICD formation. Furthermore, we found that not only pharmacological 
modulation can induce a diverse activity towards APP and Notch. Two mutants of 
Nicastrin, C2 and C3 affected APP and Notch processing to different extents (Paper 
III). This is the first study describing single residues in a γ-secretase component 
besides presenilin that differentially affect the processing of γ-secretase substrates.  
 The finding that there is a Nicastrin dependent discrepancy in APP and Notch 
processing is intriguing (Paper III). Especially since it seems like low levels of mature 
Nicastrin and low levels of active γ-secretase complexes, as observed for the C3 
mutant, is sufficient to process Notch but not APP to the same degree. One alternative 
is that the C3 mutation changes the tertiary structure of Nicastrin and thereby induces a 
conformational change of the whole complex. This could allow immature Nicastrin to 
be part of an active complex, since complex assembly and activity is not dependent on 
glycosylation of Nicastrin (Herreman et al., 2003; Shirotani et al., 2003). To investigate 
this, it would be very interesting to determine the crystal structure of Nicastrin in the 
presence and absence of the C3 mutant and study their structural differences. Such 
experiments may gain important knowledge on the overall structural conformation of 
the enzyme complex. Moreover, the function of Nicastrin whether it is involved in 
substrate recognition, gating the substrate to the active site, or a more indirect role such 
as stabilizing the complex is not completely resolved. A study by Futai et al. reports 
that the PS1 double mutant F411Y/S438P is dispensable of Nicastrin for its activity and 
that the double mutation stabilizes the complex (Futai et al., 2009). This indirectly 
indicates a stabilizing role of Nicastrin, which is in line with that the SPPL2b GxGD-
type aspartyl proteases do not require additional co-factors in order to be proteolyticly 
active (Martin et al., 2009). However, since our modifications of Nicastrin affect APP 
and Notch processing differently, these results may indicate a role for Nicastrin in 
substrate selection. Nevertheless, it would be of great interest to examine the structure 
of the catalytic site of the PS1 F411Y/S438P mutant in order to further understand the 
contribution of Nicastrin to γ-secretase processing and activity.  
 In addition, we and others have gained important information that FAD mutations 
affect the catalytic site of the γ-secretase complex (Paper I, (Berezovska et al., 2005; 
Kornilova et al., 2005)) and that these as well as pharmacological modulations (Lleo et 
al., 2004; Uemura et al., 2009) can be linked to an increased Aβ42/Aβ40 ratio. 
However, it would be very elegant to pin-point the exact structural alteration(s) that 
give rise to the mechanisms of FAD mutations proposed by Chavez-Gytierrez et al., i.e. 
leading to impairments in the initial ε-cleavage or harming the fourth cleavage 
(Aβ43>Aβ40 or Aβ42>Aβ38) (Chavez-Gutierrez et al., 2012). This is naturally a very 
challenging project, especially since there is no crystal structure of the complex 
available. Nevertheless, by using the SCAM-technique on the domains that have been 
suggested to be a part of the hydrophilic cavity (i.e. TMD1, 6, 7, 9, the GxGD and the 
PAL domains as well as the loop domain of Pen-2) (Bammens et al., 2011; Sato et al., 
2006; Sato et al., 2008; Takagi et al., 2010; Takeo et al., 2012; Tolia et al., 2006; Tolia 
et al., 2008) and compare the results obtained in the presence and absence of selected 
FAD mutations, parts of this mechanism may be elucidated. Although PS FAD 
mutations only comprise a few percent of all AD cases, understanding how their 
mechanism(s) leads to an altered Aβ-profile would gain vital insight into the 
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knowledge of the γ-secretase complex. This is crucial when developing therapeutical 
compounds for targeting the complex. In Paper II, we observed that the formation of 
both APP and Notch ICD are intact in the absence of the loop in contrast to the reduced 
Aβ levels, suggesting a differential cleavage activity between the ε-/S3- and γ-sites. 
Furthermore, we identified the ten amino acids closest to the C-terminal of the large 
hydrophilic loop to be of importance for the APP γ-site processing, reducing Aβ38-40 
levels substantially more than Aβ42. Interestingly, an array of molecules have been 
found to bind to the large loop of PS1 including β-catenin and N- and E-cadherins 
(Georgakopoulos et al., 1999; Kang et al., 1999) and they may influence its 
processing of substrates, although the loop has been shown to be dispensable for γ-
secretase activity (Xia et al., 2002). Moreover, γ-secretase interacting proteins that 
reduce Aβ levels such as TMP21 or the more recently identified VDAC, Erlin-2 or 
TPPP (Chen et al., 2006; Frykman et al., 2012; Hur et al., 2012; Teranishi et al., 2012) 
may also be possible Aβ lowering therapeutic targets. Identifying domains within PS 
(Paper II) or the other components such as Nicastrin (Paper III) that are of importance 
in differentiating between the processing of Aβ species and/or APP compared to Notch 
can be helpful in the design of GSMs or APP selective GSIs. Disparities in APP and 
Notch processing may be achieved by selectively targeting distinct γ-secretase 
complexes that exist due to the presence of PS1 and PS2 homologues and the three 
Aph-1 isoforms (Hebert et al., 2004; Saura et al., 1999; Serneels et al., 2005; Shirotani 
et al., 2004b). Moreover, PS1 containing complexes have been reported to catalyze the 
majority of the Aβ production (Borgegard et al., 2011; De Strooper et al., 1998) and 
PS1 and PS2 complexes show differences in activity and sensitivity to some γ-secretase 
inhibitors (Borgegard et al., 2011; Lai et al., 2003; Zhao et al., 2008). Indeed, it seems 
like GSIs sparing PS2 is a tolerable strategy for lowering Aβ formation (Boregård et 
al., manuscript under revision)  
 GSMs do not affect the overall rate of Notch, APP (S3and ε cleavage) or ErbB4 
processing (Kukar et al., 2008; Weggen et al., 2001). However, we found that the 
potent second generation AZ GSMs can modulate Nβ formation although to a much 
lower level than they affect Aβ formation, in contrast to the effect of first generation 
NSAIDs, R-flurbiprofen and sulindac sulfide (Paper IV). However, modulation by 
second-generation GSMs may also affect other substrate-releasing Aβ-like peptides, 
such as APP-like protein (APLP) 1 and 2, CD44 and interleukin-1 receptor II (Eggert et 
al., 2004; Kuhn et al., 2007; Lammich et al., 2002). Although the biological relevance 
of the Aβ-like peptides is unclear, it would be of great concern to investigate how this 
class of compounds affect these peptides. For example, the less amyloidogenic APLP1 
Aβ-like peptide, which is present in human CSF, has been suggested to function as a 
surrogate marker for Aβ42 in response to γ-secretase targeting drugs (Yanagida et al., 
2009). Therefore, the selectivity pattern of a given GSM should be a major 
consideration in biomarker development. 
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